Document:

<PAGE>
                                                                    Exhibit 10.3

                              INVESTMENT AGREEMENT

     THIS INVESTMENT AGREEMENT (the "Agreement") is entered into on this 3rd day
of October, 2002, by and between Hydro Med Sciences, Inc., a Delaware
corporation (the "Company"), and Paladin Labs Inc., a Canadian corporation (the
"Investor").

                                   BACKGROUND

     The Company desires to agree to issue and sell shares of its capital stock
to the Investor and the Investor desires to agree to purchase such shares from
the Company on the terms and conditions set forth herein.

                                    AGREEMENT

     NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
promises hereinafter set forth, the parties hereto, intending to be legally
bound, hereby agree as follows:

1.   AGREEMENT TO SELL AND PURCHASE.

     1.1. Initial Equity Investment.

          (a) In the event that the Company raises at least Ten Million US
Dollars ($10,000,000) in the aggregate (the "Minimum Funding Amount") in one or
more equity financing transactions consummated after the date of this Agreement
and prior to June 30, 2003, the Company shall issue and sell to the Investor,
and the Investor shall purchase from the Company, such number of shares of the
same class and series of capital stock that are sold in the equity financing
transaction in which the Company meets or exceeds the Minimum Funding Amount as
is equal to One Million US Dollars ($1,000,000) divided by the price per share
paid in such financing for an aggregate purchase price of One Million US Dollars
($1,000,000).

          (b) In connection with any equity financing transaction consummated
after the date of this Agreement and prior to June 30, 2003, if the Company has
not raised the Minimum Funding Amount upon the consummation of such transaction,
the Investor shall have the option to purchase from the Company such number of
shares of the same class and series of capital stock that are sold in such
financing transaction as is equal to One Million US Dollars ($1,000,000) divided
by the price per share paid in such financing for an aggregate purchase price of
One Million US Dollars ($1,000,000); provided, however, that if the Investor
does not invest at least One Million US Dollars ($1,000,000) in the Company by
June 30, 2003, then the Company shall have the right to terminate that certain
License Agreement by and between the Company and the Investor dated as of the
date hereof (the "License Agreement") pursuant to Section 13.2(d) thereof.

          (c) The shares purchased by the Investor pursuant to Sections l(a) or
l(b) are referred to herein as the "Initial Shares."

                                  CONFIDENTIAL                                 1
<PAGE>
     1.2. Subsequent Equity Investment.

     The Company shall have the option to issue and sell to the Investor, and
upon the exercise of such option by the Company, the Investor shall purchase
from the Company, (i) such number of shares of the same class and series of
capital stock that were sold in the then most recently completed equity
financing of the Company as is equal to Five Hundred Thousand US Dollars
($500,000) divided by the per share price paid in such financing, or (ii) if the
Company's common stock is then listed on a national securities exchange or is
quoted on NASDAQ or another quotation and reporting service, then such number of
shares of common stock as is equal to Five Hundred Thousand US Dollars
($500,000) divided by the then current market price (based on the last reported
sales price, if listed on an exchange, or the average of the last reported bid
and ask prices, if otherwise quoted) of the common stock (the "Subsequent
Shares") for an aggregate purchase price of Five Hundred Thousand US Dollars
($500,000); provided, however, that the Company may only exercise this option
upon the receipt of Regulatory Approval (as such term is defined in the License
Agreement) to market the Product (as such term is defined in the License
Agreement) within Canada and each of its territories for use in the treatment of
prostate cancer.

2.   CLOSINGS.

     2.1. Initial Closing.

     The purchase and sale of the Initial Shares shall take place at such time
as the Company and the Investor shall mutually agree (which date shall be no
later than thirty (30) days after the closing of the financing transaction in
connection with which such shares are being purchased the "Financing")) at the
offices of Pepper Hamilton LLP, 400 Berwyn Park, 899 Cassat Road, Berwyn, PA
19312, or at such other place as the Company and the Investor may mutually agree
(which time and place are designated the "Initial Closing"). At the Initial
Closing, the Company shall deliver to the Investor a certificate representing
the Initial Shares which the Investor is purchasing against delivery to the
Company by the Investor of a certified check or bank wire in the amount of the
purchase price therefor payable to the Company's order in immediately available
funds.

     2.2. Subsequent Closing.

     The purchase and sale of the Subsequent Shares shall take place at such
time as the Company and the Investor shall mutually agree (which date shall be
no later than ten (10) days after the Company notifies the Investor of its
exercise of its option to issue and sell the Subsequent Shares) at the offices
of Pepper Hamilton LLP, 400 Berwyn Park, 899 Cassat Road, Berwyn, PA 19312, or
at such other place as the Company and the Investor may mutually agree (which
time and place are designated the "Subsequent Closing", together with the
Initial Closing, the "Closings"). At the Subsequent Closing, the Company shall
deliver to the Investor a certificate representing the Subsequent Shares which
the Investor is purchasing against delivery to the Company by the Investor of a
certified check or bank wire in the amount of the purchase price therefor
payable to the Company's order in immediately available funds.

                                  CONFIDENTIAL                                 2
<PAGE>
     2.3. Terms and Conditions of Sale of Shares.

          (a) The sale of the Initial Shares shall be upon the same terms and
conditions as those contained in the Stock Purchase Agreement entered into
between the Company and the purchasers of its capital stock in the Financing
(the "Stock Purchase Agreement"), and the Investor shall become a party to, and
execute a counterpart signature page to, such Stock Purchase Agreement and all
other agreements entered into by the Company and the purchasers of its capital
stock in connection with the Financing (the "Ancillary Agreements"), and shall
have the rights and obligations of a purchaser. Notwithstanding anything to the
contrary in the Ancillary Agreements, upon joining the Ancillary Agreements the
Investor shall have the right to have one representative attend all meetings of
the Board of Directors of the Company in a nonvoting observer capacity, to
receive notice of such meetings and to receive quarterly financial statements of
the Company; provided, however, that the Company may require as a condition
precedent to the Investor's rights under this Section 2.3(a) that the Investor
and any such representative proposing to attend any meeting of the Board of
Directors and each person that shall have access to any of the information
provided by the Company to the Board of Directors shall agree to hold in
confidence and trust and to act in a fiduciary manner with respect to all
information received during such meetings or otherwise; and, provided further,
that the Company reserves the right not to provide information and to exclude
the Investor from any meeting or portion thereof if delivery of such information
or attendance at such meeting by the Investor would result in disclosure of
trade secrets to the Investor.

          (b) If the Company's common stock is not then listed on a national
securities exchange or is not quoted on NASDAQ or another quotation and
reporting service, the sale of the Subsequent Shares shall be upon the same
terms and conditions as those contained in the stock purchase agreement entered
into between the Company and the purchasers of its capital stock in the then
most recently completed equity financing of the Company (the "Subsequent Stock
Purchase Agreement"), and the Investor shall become a party to, and execute a
counterpart signature page to, such Subsequent Stock Purchase Agreement and all
other agreements entered into by the Company and the purchasers of its capital
stock in connection with such financing (the "Subsequent Ancillary Agreements"),
and shall have the rights and obligations of a purchaser thereunder.

          (c) If the Company's common stock is then listed on a national
securities exchange or is quoted on NASDAQ or another quotation and reporting
service, the sale of the Subsequent Shares shall be upon the terms and
conditions of a subscription agreement that will contain provisions customary in
such transactions (the "Subscription Agreement," collectively with the Stock
Purchase Agreement, the Ancillary Documents and the Subsequent Stock Purchase
Agreement, the "Transaction Documents").

3.   REPRESENTATIONS AND WARRANTIES.

     3.1. Representations and Warranties of Company.

     The Company represents and warrants to the Investor as follows:

                                  CONFIDENTIAL                                 3

<PAGE>
          (a) Organization and Standing.  The Company is a corporation duly
organized and validly existing under the laws of the State of Delaware.

          (b) Authorization.  The execution, delivery and performance of this
Agreement by the Company has been duly authorized by all requisite corporate
action, and this Agreement constitutes the legal, valid and binding obligation
of the Company enforceable in accordance with its terms, subject as to
enforcement of remedies to applicable bankruptcy, insolvency, reorganization or
similar laws relating to or affecting the enforcement of creditors' rights. The
execution, delivery and performance of this Agreement does not conflict with, or
result in the breach or violation of the terms, conditions or provisions of, or
constitute a default (or an event with which the giving of notice or passage of
time, or both could result in a default) under, or result in the creation or
imposition of any lien pursuant to the terms of, the Certificate of
Incorporation or the Bylaws of the Company.

          (c) Validity of Securities.  The Initial Shares and the Subsequent
Shares (together, the "Shares"), when issued, sold and delivered by the Company
in accordance with the terms of this Agreement, will be duly and validly issued,
fully-paid and nonassessable and free and clear of any liens and encumbrances.
Except as set forth in the Investor Rights Agreement dated December 27, 2001
among the Company and Investors named therein and in the Ancillary Agreements,
there are no statutory, contractual or other preemptive rights or rights of
first refusal with respect to the issuance and sale of the Shares.

          (d) Authorized and Issued Stock.  The authorized capital stock of the
Company consists of 50,000,000 shares of Common Stock, par value $.001 per
share, and 20,000,000 shares of Preferred Stock, $.001 par value. Immediately
prior to the Closing, 10,000,000 shares of Common Stock and 7,000,000 of
Preferred Stock are issued and outstanding and except as set forth on Schedule
3.1 (d), there are a) no outstanding securities, options or other rights to
acquire any capital stock or securities of the Company and b) no agreements made
by or known to the Company respecting the voting of any shares of the Company's
capital stock.

          (e) Rights of Common Stock.  The Shares shall have the rights,
preferences, privileges and restrictions of the common stock provided in the
Company's Restated Certificate of Incorporation. The Company will furnish the
Investor with copies of its Restated Certificate of Incorporation and Bylaws.
Said copies are true, correct and complete and contain all amendments through
the Closing Date.

          (f) Compliance with Law.  The Company is, and all aspects of its
business are, conducted in compliance with all applicable laws, ordinances and
regulations, inclusive of those of any administrative boards or agencies or
other public authorities having jurisdiction, the non-compliance with which
would have material adverse effects on the Company or its operations.

          (g) Financial Statements.  The Company will deliver to the Investor
the audited consolidated financial statements of the Company for the year ended
December 31,2001 and the audited or if not available, the unaudited financial
statements for the quarter ended June

                                  CONFIDENTIAL                                 4
<PAGE>
30, 2002 (hereinafter collectively referred to as "Financial Statements"). The
Financial Statements:

               (i) reflect accurately in all material respects the transactions
entered into the books and accounts of the Company, as at the dates thereof;

               (ii) present fairly in all material respects the assets,
liabilities, retained earnings, profit and loss and financial position of the
Company as at the dates thereof;

               (iii) have been prepared in accordance with generally accepted
accounting principles, consistently applied, except for the absence of footnote
information in the Company's unaudited Financial Statements; and

               (iv) except to the extent reflected or reserved against thereon,
the Company does not have on the dates thereof any liabilities or obligations of
any nature, whether direct or indirect, accrued, absolute, contingent,
unasserted or otherwise, known or unknown, fixed or unfixed, liquidated or
unliquidated including, without limitation, federal, provincial, local,
municipal or other tax liabilities due or to become due or penalties,
assessments or interest charges in respect thereof, or unusual forward or long
term commitments or unrealized or anticipated losses from any unfavorable
commitments, except for liabilities that have been incurred in the ordinary
course of the Company's business since June 30, 2002 or liabilities which, in
the aggregate, are not material.

          (h) No Conflict.  The execution and delivery of this Agreement does
not, and the consummation of the transactions contemplated hereby will not,
conflict with, or result in any violation of, or default (with or without notice
or lapse of time, or both), or give rise to a right of termination, cancellation
or acceleration of any obligation or to a loss of a material benefit under any
provision of the Restated Certificate of Incorporation or Bylaws of Hydro Med or
any mortgage, indenture, lease or other agreement or instrument, permit,
concession, franchise, license, judgment, order, decree, statute, law,
ordinance, rule or regulation applicable to Hydro Med, its properties or assets,
which conflict, violation, default or right would have a material adverse effect
on the business, properties, prospects or financial condition of Hydro Med.

          (i) Title to Assets.  The Company has good and marketable title to its
material properties and assets, and has good title to all its leasehold
interests, in each case subject to no mortgage, pledge, lien, lease, encumbrance
or charge, other than the lien of current taxes not yet due and payable or which
are being contested in good faith, and possible minor liens and encumbrances
which do not in any case materially detract from the value of the property
subject thereto or materially impair the operations of the Company, and which
have not arisen otherwise than in the ordinary course of business.

          (j) Litigation.  There are no pending or, to the best of Hydro Med's
knowledge, threatened lawsuit, administrative proceeding, arbitration, labor
dispute or governmental investigation ("Litigation") to which Hydro Med is a
party or by which any material portion of its assets, taken as a whole, may be
bound, which Litigation, if adversely determined, would have a material adverse
effect on the business, properties, prospects or financial condition of Hydro
Med. Hydro Med is not a party or subject to the provisions of any

                                  CONFIDENTIAL                                 5
<PAGE>
order, writ, injunction, judgment, or decree of any court or governmental agency
or instrumentality. There is no action, suit, proceeding, or investigation by
Hydro Med currently pending or that Hydro Med intends to initiate.

          (k) No material default.  Hydro Med is not in violation of or default
under any provision of (a) its Restated Certificate of Incorporation or Bylaws
or (b) any mortgage, indenture, lease or other agreement or instrument, permit,
concession, franchise or license to which it is a party of by which it is bound
or (c) any federal or state judgment, order, decree, statute, law, ordinance,
rule or regulation applicable to Hydro Med, except with respect to clauses (b)
and (c) above, such violations or defaults as would not have a material adverse
effect on the business, properties, prospects or financial condition of Hydro
Med.

          (1) Disclosure.  No representation or warranty of Hydro Med contained
in this Agreement contains any untrue statement of a material fact or omits to
state a material fact necessary in order to make the statements contained in
this Agreement not misleading in light of the circumstances under which they
were made.

          (m) Solvency, no default.  As of this date the Company has sufficient
funds and cask flow to pay its debts and other liabilities as they become due,
and the Company is not in default with respect to any material debt or
liability.

          (n) No bankruptcy.  There has not been filed any petition or
application, or any proceeding commenced which has not been discharged, by or
against the Company with respect to any assets of the Company under any law,
domestic or foreign, relating to bankruptcy, reorganization, fraudulent
transfer, compromise, arrangements, insolvency, readjustment of debt or
creditors' rights, and no assignment has been made by the Company for the
benefit of its creditors.

     3.2. Representations and Warranties of Investor.

     The Investor represents and warrants to the Company as follows:

          (a) Organization and Standing.  The Investor is a corporation duly
organized and validly existing under the laws of Canada.

          (b) Authorization.  The execution, delivery and performance of this
Agreement by the Investor has been duly authorized by all requisite corporate
action (including approval to purchase the Initial Shares and the Subsequent
Shares (collectively, the "Shares")), and this Agreement constitutes the legal,
valid and binding obligation of the Investor enforceable in accordance with its
terms, subject as to enforcement of remedies to applicable bankruptcy,
insolvency, reorganization or similar laws relating to or affecting the
enforcement of creditors' rights. The execution, delivery and performance of
this Agreement does not conflict with, or result in the breach or violation of
the terms, conditions or provisions of, or constitute a default (or an event
with which the giving of notice or passage of time, or both could result in a
default) under, or result in the creation or imposition of any lien pursuant to
the terms of, the Certificate of Incorporation or the Bylaws of the Investor.

                                  CONFIDENTIAL                                 6
<PAGE>
          (c) Purchase for Investment.  The Investor shall be purchasing the
Shares for investment for Investor's own account only and not with a view to, or
for resale in connection with any "distribution" thereof within the meaning of
the Securities Act of 1933, as amended (the "Securities Act"). The Investor will
not sell, pledge, grant an interest in or otherwise transfer the Shares or any
part thereof unless (a) the Shares are registered under the Securities Act and
any other applicable securities act, or (b) in the opinion of counsel to the
Company, an exemption from the registration requirements of the Act and any
other applicable securities act is available and such transfer complies with the
provisions of Regulation S as promulgated by the United States Securities and
Exchange Commission under the Securities Act.

          (d) Investor Suitability Standards.  The Investor represents,
warrants, covenants and acknowledges that neither the Company nor any person
acting on its behalf offered to sell the Shares by means of a form of general
advertising or conducted any direct selling efforts in the United States with
respect to the Shares.

          (e) Investment Experience.  The Investor is aware of the Company's
business affairs and financial condition, has had sufficient opportunity to ask
questions of and receive answers from representatives of the Company and has
acquired sufficient information about the Company to reach an informed and
knowledgeable decision to purchase the Shares. The Investor is experienced in
evaluating and investing in securities of companies in the development stage and
acknowledges that it is able to fend for itself, can bear the economic risk of
its investment, and has such knowledge and experience in financial and business
matters as to capable of evaluating the merits and risks of investing in the
Shares, including a complete loss of its investment.

          (f) Foreign Investor.  The Investor hereby represents that it has
satisfied itself as to the full observance of the laws of its jurisdiction in
connection with any invitation to purchase the Shares or any use of this
Agreement, including (i) the legal requirements within its jurisdiction for the
purchase of the Shares, (ii) any foreign exchange restriction applicable to such
purchase of the Shares; (iii) any governmental or other consents that may need
to be obtained, and (iv) the income tax and other tax consequences, if any, that
may be relevant to the purchase, holding, redemption, sale or transfer of the
Shares. Such Investor's purchase and payment for, and its continued beneficial
ownership of the Shares, will not violate any applicable securities; or other
laws of its jurisdiction.

          (g) Holding Periods; Legends.  The Investor further acknowledges and
understands that the Shares must be held indefinitely unless they are
subsequently registered under the Securities Act or an exemption from such
registration is available. The Investor understands that such Shares, when
issued, will be imprinted with a legend that prohibits the transfer of such
Shares, unless they are registered or such registration is not required in the
opinion of counsel for the Company.

          (h) Restricted Shares.  The Investor acknowledges that the Shares,
when issued, shall not have been registered under the Securities Act or any
other applicable securities act and are characterized as "restricted
securities". Under the Securities Act and applicable regulations, such
securities may be resold without registration under the Securities Act only in
certain limited circumstances. In this connection, Investor represents that it
is familiar with

                                  CONFIDENTIAL                                 7
<PAGE>
Regulation S of the Securities Act, as presently in effect, and understands the
resale limitations imposed thereby and by the Securities Act.

          (i) No Market.  The Investor further understands that, at the time the
Investor wishes to sell the Shares, there may be no public market upon which to
make such a sale.

4. COVENANTS OF INVESTOR IN CONNECTION WITH CLOSINGS.

     4.1. In connection with the Closings:

          (a) Performance.  The Investor shall have performed and complied with
all agreements and conditions herein required to be performed or complied with
by the Investor on or before the Closings.

          (b) Consents.  The Investor shall use its best efforts to obtain all
approvals and consents required to be obtained by the Investor in order to
consummate the purchase and sale of the Shares contemplated hereby.

          (c) Fulfillment of Conditions; Compliance with Agreement.  The
Investor shall use commercially reasonable efforts to fulfill the conditions
applicable to it set forth in the Transaction Documents, including the execution
and delivery of the Transaction Documents and the taking of such actions as may
be necessary to fulfill such conditions. The Investor shall also use
commercially reasonable efforts to do all such acts and take all such measures
as may be reasonably necessary, proper or advisable to comply with the
representations, agreements, conditions and other provisions of this Agreement
and the Transaction Documents and consummate the purchase and sale of Shares as
contemplated hereby.

5. MISCELLANEOUS.

     5.1. Governing Law.

     This Agreement shall be governed in all respects by the laws of the State
of Delaware as such laws are applied to agreements between Delaware residents
entered into and performed entirely in Delaware.

     5.2. Successors and Assigns.

     This Agreement shall bind and benefit the successors, assigns, heirs,
executors and administrators of the parties (including without limitation, any
successor corporation to the Company). The rights of the Investor under this
Agreement may not be assigned without the written consent of the Company.

     5.3. Entire Agreement.

     This Agreement and the other documents delivered pursuant hereto constitute
the full and entire understanding and agreement between the parties with regard
to the Investor's purchase and the Company's sale of the Shares, supercede all
prior agreements and understandings with

                                  CONFIDENTIAL                                 8
<PAGE>
respect to the Company's sale of the Shares, and may be amended only in a
writing signed by the Company and the Investor.

     5.4. Severability.

     If one or more provisions of this Agreement are held to be invalid, illegal
or unenforceable under applicable law, such provision shall be excluded from
this Agreement and the balance of this Agreement shall be interpreted as if such
provision were so excluded and the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby.

     5.5. Amendments and Modifications

     This Agreement may be amended, waived, changed, modified or discharged only
by an agreement in writing signed by all of the parties.

     5.6. Delays or Omissions.

     It is agreed that no delay or omission to exercise any right, power or
remedy accruing to any party, upon any breach, default or noncompliance by
another party under this Agreement, shall impair any such right, power or
remedy, nor shall it be construed to be a waiver of any such breach, default or
noncompliance, or any acquiescence therein, or of or in any similar breach,
default or noncompliance thereafter occurring. It is further agreed that any
waiver, permit, consent or approval of any kind or character on either the
Company's or the Investor's part of any breach, default or noncompliance under
this Agreement or any waiver on such party's part of any provisions or
conditions of the Agreement must be in writing and shall be effective only to
the extent specifically set forth in such writing. All remedies, either under
this Agreement, by law, or otherwise afforded to any party shall be cumulative
and not alternative.

     5.7. Notices.

     All notices required or permitted hereunder shall be in writing and shall
be deemed effectively given: (a) upon personal delivery to the party to be
notified, (b) when sent by confirmed telex or facsimile if sent during normal
business hours of the recipient, if not, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt
requested, postage prepaid, or (d) one (1) day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company at the
address as set forth on the signature page hereof and to the Investor at the
address set forth on the signature page hereto or at such other address as the
Company or the Investor may designate by ten (10) days advance written notice to
the other parties hereto.

     5.8. Attorneys' Fees,

     In the event that any suit or action is instituted to enforce any provision
in this Agreement, the prevailing party in such dispute shall be entitled to
recover from the losing party all fees, costs and expenses of enforcing any
right of such prevailing party under or with respect

                                  CONFIDENTIAL                                 9
<PAGE>
to this Agreement, including without limitation, such reasonable fees and
expenses of attorneys and accountants, which shall include, without limitation,
all fees, costs and expenses of appeals.

     5.9. Titles and Subtitles.

     The titles of the sections and subsections of the Agreement are for
convenience of reference only and are not to be considered in construing or
interpreting this Agreement.

     5.10. Counterparts.

     This Agreement may be executed in one or more counterparts, each of which
shall be deemed an original, but all of which taken together shall constitute a
single agreement.

     5.11. Finder's Fees.

     Each party represents that it neither is nor will be obligated for any
finder's fee or commission in connection with the transactions contemplated by
this Agreement. The Investor agrees to indemnify and hold harmless the Company
from any liability for any commission or compensation in the nature of a
finder's fee (and the costs and expenses of defending against such liability or
asserted liability) for which the Investor or any of the Investor's officers,
employees or representatives is responsible. The Company agrees to indemnify and
hold harmless the Investor from any liability for any commission or compensation
in the nature of a finder's fee (and the costs and expenses of defending against
such liability or asserted liability) for which the Company or any of its
officers, employees or representatives is responsible.

     5.12. Pronouns.

     All pronouns contained herein, and any variations thereof, shall be deemed
to refer to the masculine, feminine or neutral, singular or plural, as to the
identity of the parties hereto may require.

     5.13. Further Actions.

     The parties shall take such actions and execute and deliver such
instruments and documents as may reasonably be required from time to time to
effect and complete the transactions contemplated by this Agreement, including,
without limitation, the Stock Purchase Agreement, the Investors Rights Agreement
and the Co-Sale Agreement.

                     [REMAINDER OF PAGE INTENTIONALLY BLANK]

                                  CONFIDENTIAL                                10
<PAGE>
     IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement
as of the day and year first above written.

                                    COMPANY

                                        HYDRO MED SCIENCES, INC.
                                        8 Clark Drive
                                        Cranbury, NJ 08512

                                        By: /s/ David Tierney
                                            ------------------------------------
                                        Name: David Tierney
                                        Title: President & CEO

                                    INVESTOR

                                        PALADIN LABS INC.
                                        6111 Royalmount Avenue
                                        Suite 102
                                        Montreal, Quebec, H4P 2T4

                                        By: /s/ Jonathan Goodman
                                            ------------------------------------
                                        Name: Jonathan Goodman
                                        Title: President & CEO

                                  CONFIDENTIAL                                11
<PAGE>
                                 Schedule 3.l(d)

                                 Capitalization

<Table>
<Caption>
                                                                       Percent
                                                                 -------------------
                                           Number of Common                 Fully
                                        Stock Equivalents Held   Basic   Distributed
                                        ----------------------   -----   -----------
<S>                                     <C>                      <C>     <C>
Preferred Stockholders

SMH Hydro Med LLC(l)                           4,000,000          23.5%      21.4%
Corporate Opportunities Fund, L.P. (1)         2,000,000          11.8%      10.7%
Wheatley Medtech Partners, L.P.                1,000,000           5.9%       5.3%
                                              ----------         -----      -----
   Total preferred shares                      7,000,000          41.2%      37.4%

Common Stockholders

GP Strategies (2)                             10,000,000          58.8%      53.5%
                                              ----------         -----      -----
   Total shares outstanding                   10,000,000         100.0%      90.9%
                                                                 =====

Option Holders

Incentive stock option pool                    1,700,000                      9.1%
                                              ----------                    -----
Total fully distributed shares                18,700,000                    100.0%
                                              ==========                    =====
</Table>
----------
(1)  Affiliate of Sanders Morris Harris, Inc.

(2)  Corporate Opportunities Fund, L.P. has the option to exchange the Notes (as
     defined below) for 1,999,000 shares of common stock currently held by GP
     Strategies.

          On July 7, 2000, GP Strategies, in a transaction with Corporate
Opportunities Fund, L.P. (an affiliate of Sanders Morris Harris), received
approximately $2.6 million in exchange for 6% Convertible Exchangeable Notes
due June 30, 2003 (the "Notes"). The Notes, at the option of the holders, may be
exchanged for 1,999,000 shares of common stock of the Company currently held by
GP Strategies. The holders of the Notes can convert or exchange at any time
prior to June 30, 2003.

                                  CONFIDENTIAL                                12<PAGE>
                                                                    Exhibit 10.4

                       LICENSE AND DISTRIBUTION AGREEMENT

     THIS LICENSE AND DISTRIBUTION AGREEMENT is entered into as of the 17th day
of September 2003, by and between VALERA PHARMACEUTICALS, INC. (formerly known
as Hydro Med Sciences, Inc.), a corporation incorporated under the laws of the
state of Delaware, U.S.A., with its principal place of business located at 8
Clarke Drive, Cranbury, New Jersey 08512-3617 ("VALERA"), and KEY ONCOLOGICS
(PTY) LTD, a limited company formed under the laws of South Africa, with its
principal place of business located at 171 Katherine Road, Building 1, Sandton,
South Africa ("KEY").

                                   BACKGROUND

     WHEREAS Key is engaged in the marketing, sale and distribution of various
pharmaceutical products used in the treatment of cancer in South Africa;

     WHEREAS Valera has developed and is the sole owner or exclusive licensee of
certain Patent Rights and other Intellectual Property (as defined below)
relating to a certain Product (as defined below) and is currently in the process
of conducting clinical trials for the Product for use in the treatment of
prostate cancer;

     WHEREAS Valera wishes to appoint Key as its exclusive agent in the
Territory in seeking to obtain Regulatory Approval (as defined below) for the
Product in the Territory for use in the Primary Indication, the whole in
accordance with the terms and conditions set forth in this Agreement;

     WHEREAS Valera wishes to appoint Key as the exclusive distributor of the
Product in the Territory for use in the Primary Indication, the whole in
accordance with the terms and conditions set forth in this Agreement;

     WHEREAS Key desires Valera to supply Key with the Product on an exclusive
basis in the Territory prior to Regulatory Approval, and following receipt of
Regulatory Approval, for distribution and sale in the Territory for use in the
Primary Indication, the whole in accordance with the terms and conditions set
forth in this Agreement.

                                      TERMS

     NOW, THEREFORE, in consideration of the respective covenants, agreements,
representations, warranties and indemnities contained in this Agreement and for
other good and valuable consideration, Key and Valera hereby covenant and agree
as follows:

                   ARTICLE 1 - DEFINITIONS AND INTERPRETATION

     1.1 DEFINITIONS.  For the purposes of this Agreement or any notice,
consent, authorization or other communication required or permitted to be given
under this Agreement, the following expressions shall have the following
meanings, respectively, unless the context otherwise requires:

                                  CONFIDENTIAL
<PAGE>
                                                                               2

          (a) "AFFILIATE" shall mean any Person which directly or indirectly
controls, is controlled by, or is under common control with another Person,
provided that "control" shall mean ownership as to more than fifty percent (50%)
of another Person or the power to direct decisions of another Person, including,
without limitation, the power to direct management and policies of another
Person, whether by reason of ownership, by contract or otherwise.

          (b) "AGREEMENT" shall mean this License and Distribution Agreement, as
amended from time to time.

          (c) "BUSINESS DAY" shall mean any day other than a Saturday, Sunday or
other day on which the branches of [INSERT SOUTH AFRICAN BANK] located in
[INSERT LOCATION] and/or the Federal Reserve Bank with jurisdiction over the
then-current principal place of business by Valera are not open for business.

          (d) "CALENDAR QUARTER" shall mean each three-month period commencing
January 1, April 1, July 1 and October 1 of each year during the term of this
Agreement.

          (e) "CALENDAR YEAR" shall mean the period from January 1st to December
31st in a given year.

          (f) "CMC INFORMATION" shall mean the chemistry, manufacturing, and
control information as commonly found in a NDA.

          (g) "COMMERCIAL SALE" means any sale or distribution of the Product by
Key or its Affiliates to a Third Party, other than (i) distribution in
connection with Phase IV clinical trials of the Product conducted by Key or (ii)
distribution of samples in accordance with Section 3.8.

          (h) "DEVELOPMENT PLAN" shall have the meaning set forth in Section
2.3.

          (i) "DOLLAR" and the symbol "$" shall mean lawful money of the United
States.

          (j) "EFFECTIVE DATE" shall mean the date first written above.

          (k) "EVENT OF FORCE MAJEURE" shall have the meaning set forth in
Section 13.1.

          (l) "GMPs" shall mean Good Manufacturing Practices as required under
the rules and regulations of the United States Food and Drug Administration.

          (m) "GOVERNMENTAL BODY" shall mean (i) any national, federal,
provincial, state, municipal or other government or body with jurisdiction over
all or any part of the Territory, (ii) any subdivision, ministry, department,
secretariat, bureau, agency, commission, board, instrumentality or authority of
any of the foregoing governments or bodies, (iii) any quasi-governmental or
private body exercising any regulatory, expropriation or taxing authority under
or for the account of any of the foregoing governments or bodies, or (iv) any
domestic or foreign

                                  CONFIDENTIAL
<PAGE>
                                                                               3

judicial, quasi-judicial, arbitration or administrative court, grand jury,
tribunal, commission, board or panel of any of the foregoing governments or
bodies.

          (n) "IMPLANT" means Valera's proprietary Histrelin Hydron Implant(TM),
as more fully described in Schedule l.l(n).

          (o) "IMPROVEMENTS" shall mean any re-formulations, line-extensions or
other advances in, modifications or improvements to the Product for use in the
Primary Indication.

          (p) "KIT" shall mean a container and its components assembled and
packaged by Valera or a third party designated by Valera, containing the Implant
and the materials and accessories listed on Schedule 1.1 (p).

          (q) "LABELS" shall mean (i) all labels and other written, printed, or
graphic matter upon the Product or any packaging, container or wrapper utilized
with the Product and (ii) any written material accompanying the Product,
including without limitation, any package inserts.

          (r) "LAWS" shall mean:

     1.1 all constitutions, treaties, laws, statutes, codes, ordinances, orders,
decrees, rules, regulations, and municipal by-laws, whether domestic, foreign or
international, including any such constitutions, etc. of any Governmental Body;

     1.2 all judgments, orders, writs, injunctions, decisions, rulings, decrees
and awards of any Governmental Body; and

     1.3 all policies, practices and guidelines of any Governmental Body, in
each case binding on or affecting the Party or Person referred to in the context
in which such word is used; and "Law" shall mean any one of them.

          (s) "LOSSES" shall mean liabilities, damages, costs or expenses,
including reasonable fees and expenses of attorneys and other professionals, as
well as court costs.

          (t) "MARKETING PLAN" shall have the meaning set forth in Section 3.10.

          (u) "MATERIAL BREACH" shall mean any breach of the terms of this
Agreement of such a nature as to have a material effect on the non-breaching
Party.

          (v) "NDA" shall mean a New Drug Application filed with the South
African Regulatory Authorities.

          (w) "NET SALES" shall mean the gross amount actually collected by Key
and its Affiliates with respect to the Commercial Sale of the Product in the
Territory, less the aggregate of (i) customers' returns for Product that fails
to comply with Specifications or that are made in accordance with the Returns
Policy attached to Schedule 6.9, rebates pursuant to any governmental programs
or Laws, recalls, trade and/or promotional allowances actually allowed or taken;
(ii) amounts collected for freight, transport and delivery, including insurance,
for

                                  CONFIDENTIAL
<PAGE>
                                                                               4

shipping from Key's or its designee's facilities to a customer (but only to the
extent of the actual cost of such freight, transport and delivery charges), and
(iii) any sales tax, value added tax, goods and services tax or any other tax
that may be imposed on the sale of the Product, which taxes are included in
gross amount collected by Key and its Affiliates.

          (x) "PARTIES" shall mean Key or Valera collectively; and "PARTY" shall
mean either one of them.

          (y) "PERSON" shall mean an individual, corporation, limited liability
company, co-operative, partnership, organization or any similar entity.

          (z) "PRIMARY INDICATION" shall mean the treatment of prostate cancer.

          (aa) "PRODUCT" shall mean all dosage strengths and forms of the
Implant in its final finished form along with the Kit, together with all Labels
and any and all Improvements.

          (bb) "PROMOTIONAL MATERIALS" shall mean all promotional materials,
detail aids and pieces, journal ads, films, artwork and graphics, and any other
marketing literature and information relating to the marketing, distribution or
sale of the Product for use in the Primary Indication outside of the Territory.

          (cc) "REGULATORY APPROVAL" shall mean the approval by all Regulatory
Authorities of the NDA and the receipt by Key of the other approvals, licenses,
registrations and authorizations of all Regulatory Authorities necessary for the
marketing, distribution and sale of the Product in the Territory for use in the
Primary Indication.

          (dd) "REGULATORY AUTHORITY" shall mean each and every Governmental
Body from which approvals are required for the marketing, distribution or sale
of the Product in the Territory.

          (ee) "REJECTED PRODUCT" shall have the meaning set forth in Section
6.5.1.

          (ff) "SPECIFICATIONS" shall mean the specifications for the Product
approved by the Regulatory Authorities, to be attached as Schedule 1.1 (ff) and
more fully described in the official Labels for the Product.

          (gg) "TERM" shall mean the time period from the Effective Date until
expiration or earlier termination of this Agreement.

          (hh) "TERRITORY" shall mean South Africa and each of its territories
and possessions on the Effective Date.

          (ii) "THIRD PARTY" means any Person other than a Party or an Affiliate
of a Party.

          (jj) "TRADE MARKS" shall mean, subject to Article 4, all trade marks
and trade names and trade dresses (whether registered or not) owned by Valera or
its Affiliates and

                                  CONFIDENTIAL
<PAGE>
                                                                               5

approved by Valera for use in the marketing, distribution and sale of the
Product in the Territory for use in the Primary Indication.

     1.2 INTERPRETATION.  The division of this Agreement into Articles and the
insertion of headings are for convenience of reference only and shall not
affect the interpretation of this Agreement. In this Agreement, words importing
the singular number only shall include the plural and vice versa and words
importing gender shall include all genders.

     1.3 SCHEDULES.  The following are the Schedules annexed to and incorporated
(or will be annexed to and incorporated) in this Agreement by reference and
deemed to be a part hereof:

<TABLE>
<S>                <C>
Schedule 1.1(n)    Current Implant Specifications
Schedule 1.1(p)    Contents of Kit
Schedule 1.1(ff)   Product and Kit Specifications
Schedule 5.2       Technical Manufacturing Requirements
Schedule 6.9       Returns Policy
</TABLE>

             ARTICLE 2 - PRODUCT DEVELOPMENT AND REGULATORY APPROVAL

     2.1 REGULATORY APPROVAL.  Valera hereby appoints Key as its exclusive agent
in the Territory during the Term, and Key hereby accepts its appointment, upon
the terms and conditions herein specified, to apply for each Regulatory Approval
for the Product for use in the Primary Indication. Key hereby agrees to use
commercially reasonable efforts in applying for each such Regulatory Approval,
which shall, whenever permitted by Law, be applied for in the name of Valera
and be substantially similar to the Regulatory Approval in effect in the United
States as it relates to manufacturing, testing, packaging, quality control,
quality assurance and other processes (except for the Labels which shall be
tailored for the Territory). Valera undertakes, at its own expense, to provide
Key with such assistance and cooperation to the extent necessary to obtain each
such Regulatory Approval for the Product for use in the Primary Indication. The
Parties agree to set up a meeting with each Regulatory Authority prior to
submitting the NDA for the Product and to undertake appropriate follow-up
procedures in order to increase the chances of success in obtaining Regulatory
Approval for the Product for use in the Primary Indication.

     2.2 FURNISHING DATA.  Valera shall supply Key with all data and information
in its possession or control as is necessary for the purpose of obtaining
Regulatory Approval for the Product in the Territory for use in the Primary
Indication, including, but not limited, to clinical and non-clinical study data,
results and reports (including toxicology reports) and/or CMC information owned
or used by Valera with respect to the Product, and Valera may, in its
discretion, make its personnel available as needed to address any regulatory
issues as they arise. Without limiting the generality of the foregoing, Valera
shall provide Key with access to and the right to cross-reference existing
regulatory filings for the Product submitted by it and/or its Affiliates or
designated nominees in any jurisdiction outside of the Territory. At the request
of Key, Valera shall notify the Regulatory Authority in the Territory of Key's
right to reference any such regulatory filings in any application filed by Key
in accordance with the terms of this Agreement.

                                  CONFIDENTIAL
<PAGE>
                                                                               6

     2.3 DEVELOPMENT AND REGULATORY APPROVAL PLAN FOR THE PRIMARY INDICATION.
Within sixty (60) Business Days after the Effective Date, Key and Valera shall
prepare a plan outlining all pre-clinical, clinical and regulatory activities
that are necessary for receiving Regulatory Approval for the use of the Product
in the Primary Indication in the Territory, the party responsible for each such
activity and estimated time schedules for the completion of all such activities
(the "PLAN"). Generally, the Plan shall allocate responsibility for pre-clinical
and clinical activities to Valera and regulatory activities in the Territory
(including development and approval of the Labels) to Key; provided that in no
event shall the Plan require Valera to conduct pre-clinical or clinical
activities beyond those activities currently being conducted by Valera in the
United States in respect of the Primary Indication. Each Party shall use
commercially reasonable efforts to perform their respective responsibilities
under the Plan within the schedule set forth in the Plan. Each Party shall
provide the other Party with regular (but no less than quarterly) updates on its
progress against the Plan.

     2.4 PHASE IV CLINICAL STUDIES.  Key shall have the exclusive right (but not
the obligation) to conduct Phase IV clinical trials relating to the use of the
Product in the Primary Indication in the Territory, but only with the prior
written consent of Valera, which consent shall not be unreasonably withheld or
delayed; provided that if Key fails to conduct such Phase IV clinical trial
within one (1) year after a request by Valera to conduct such a study, Valera
shall have the right to conduct Phase IV clinical trials relating to use of the
Product in the Primary Indication in the Territory. For the purpose of
conducting such Phase IV clinical trials, Valera shall supply to Key a
commercially reasonable quantity of the Product at a price equal to Valera's
manufacturing cost. All clinical and/or marketing data developed by the Parties
during the Term shall remain the property of the Party developing such data, and
any data to which both Parties have contributed to or on which both Parties have
worked shall remain the property of both jointly and severally worldwide;
provided that Valera shall have a perpetual, irrevocable, royalty-free, fully
paid-up license to copy, disclose and use in any manner any and all clinical
and/or marketing data developed in the course of such Phase TV trials and not
otherwise owned by Valera. The Parties agree that they will promptly share with
one another all information and reports regarding the results of any such Phase
IV trials.

     2.5 MAINTAINING REGULATORY APPROVAL.  Key undertakes to use commercially
reasonable efforts to maintain the Regulatory Approval for the Product for use
in the Primary Indication in the Territory. Valera undertakes to assist in
maintaining such Regulatory Approval, in accordance with Key's reasonable
requests. Subject to the foregoing, all reasonable direct out-of-pocket expenses
incurred by Key and/or Valera in maintaining the registrations shall be borne
and reimbursed by Key.

     2.6 COPIES OF CORRESPONDENCE; NOTICE.  Copies of all pertinent
correspondence related to the promotion, sale and use of the Product for use in
the Primary Indication to and from all Regulatory Authorities and all
submissions, or pertinent excerpts thereof, to the Regulatory Authorities
connected to the Product for use in the Primary Indication will be furnished by
the corresponding Party to the other Party in a timely manner.

     2.7 REIMBURSEMENT.  Key shall, at its own expense, make all submissions and
filings to each Government Body and all other Third Parties necessary or
desirable to establish unit prices for the Product for use in the Primary
Indication in the Territory.

                                  CONFIDENTIAL
<PAGE>
                                                                               7

             ARTICLE 3 - EXCLUSIVE DISTRIBUTION; PROMOTION AND SALES

     3.1 APPOINTMENT OF DISTRIBUTOR.  Subject to the terms and conditions of
this Agreement, Valera hereby appoints Key during the Term, and Key hereby
accepts its appointment, as exclusive distributor of the Product in the
Territory for the Primary Indication.

     3.2 EXCLUSIVE SUPPLY.  During the Term, Valera shall not supply the Product
for distribution or sale in the Territory for use in the Primary Indication to
any Person other than Key, it being understood between the Parties that Valera
shall not directly or indirectly sell, or otherwise make available, the Product
in the Territory for use in the Primary Indication other than through Key in
accordance with the terms of this Agreement. Valera shall refer to Key all
orders or inquiries received by it from sources in the Territory in connection
with the Product for use in the Primary Indication.

     3.3 RESERVATION OF RIGHTS.  In no event shall this Agreement be construed
to prevent Valera from directly or indirectly: (a) manufacturing, using,
marketing, promoting, distributing and selling the Product in the Territory for
use in indications other than the Primary Indication; (b) manufacturing, using,
marketing, promoting, distributing and selling the Product outside the Territory
for use in any indication; or (c) entering into and performing agreements with
third parties regarding the foregoing.

     3.4 SALES WITHIN THE TERRITORY.  Key shall not, and Key shall cause its
Affiliates not to, directly or indirectly, without the prior written consent of
Valera, sell the Product outside the Territory, or knowingly sell the Product to
any Person within the Territory for resale or use outside of the Territory.

     3.5 COMPETING PRODUCT.  Key shall not, and shall cause its Affiliates not
to, directly or indirectly, jointly or in conjunction with any other Person,
whether as principal, agent, shareholder, employee, independent contractor, or
in any other manner whatsoever, develop, market, distribute or sell in the
Territory any products that contain the same active ingredient as that which is
contained in the Product, or any products similar to or competitive with the
Product, that are used in the Primary Indication, during the Term and for a
period of three(3) years following the expiry or termination of this Agreement,
except that Key may market, distribute and sell Eligard(TM) 7.5mg, Eligard
22.5mg and Eligard 30mg under the terms of the [EXCLUSIVE LICENSE AGREEMENT
BETWEEN KEY AND ATRIX LABORATORIES, INC. DATED 22 AUGUST 2002].

     3.6 SUBCONTRACTING.  The Parties acknowledge and agree that, subject to
prior written notification to and acceptance from the appropriate Regulatory
Authority, each Party shall have the right, at its sole expense, to subcontract
with Third Parties or Affiliates for the performance of its obligations
hereunder, upon prior written approval of the other Party where the
subcontractor is a Third Party (which approval shall not be unreasonably
withheld or delayed); provided, however, that each Party shall remain
responsible to the other Party for (a) assuring that each subcontractor complies
with all applicable provisions of this Agreement and all applicable Laws and (b)
fulfilling all of its obligations hereunder; and provided further that Key shall
have no right to approve or disapprove of any contract manufacturer or contract
packager engaged by Valera. In the event that any subcontracting by Valera would
have a material impact

                                  CONFIDENTIAL
<PAGE>
                                                                               8

on Key's responsibilities to the appropriate Regulatory Authority and to the
extent reasonably possible, Valera will inform Key at least six (6) months prior
to arranging for any such subcontracting.

     3.7 PRODUCT PROMOTION.  Key shall employ its best efforts to market,
distribute and sell the Product in the Territory for use in the Primary
Indication and shall bear all costs and expenses incurred in connection with
such efforts, except as set forth in this Agreement. The Parties agree to meet
at either Party's request in order to discuss any marketing, distribution and
sales issues.

     3.8 SAMPLES.  During the first three (3) years from the date the Product is
launched in the Territory, Valera shall provide to Key samples of the Product at
a price equal to Valera's manufacturing cost. Sample quantities shall be limited
to supplying evaluation units to an advisory board for example, or key
physicians as identified by Key and approved by Valera acting reasonably, and
not to be used as a promotional tool for the broad mass of the Territory's
physicians.

     3.9 PROMOTIONAL MATERIALS.  Valera shall provide Key, at no additional
cost, with samples of all Promotional Materials owned by Valera to market the
Product for use in the Primary Indication outside of the Territory; provided
that Key reimburses Valera for all additional advertising agency costs, if any,
associated with supplying any artwork and graphics. Valera hereby grants to Key
the right to use such Promotional Materials and, subject to Article 4, to modify
any artwork and graphics for its purpose.

     3.10 MARKETING PLAN.  Commencing in the year in which Key submits the NDA
to the Regulatory Authorities, Key shall prepare, develop and submit to Valera
an annual marketing plan (the "MARKETING PLAN") for Valera's review and approval
by no later than the 15th of February of each year during the term of this
Agreement, for the then current Calendar Year. The Marketing Plan will outline
plans for the promotion and sale of the Product in the Territory, and will also
include recommendations for Product pricing, reimbursement status and
activities, positioning, and a description of the promotional programs, if any,
planned for the relevant Calendar Year. Valera, acting in good faith, shall have
thirty (30) Business Days from the date of receipt to review the Marketing Plan
and suggest commercially reasonable changes. Key shall make commercially
reasonable efforts to include any changes in the Marketing Plan suggested by
Valera and shall advise, in writing, within fifteen (15) Business Days which
changes it has incorporated together with an explanation as to any changes that
were suggested by Valera but not incorporated. In the event that Valera does not
respond to Key within thirty (30) Business Days of the receipt of the Marketing
Plan, the Marketing Plan will be deemed to be acceptable to Valera.
Notwithstanding anything else contained herein to the contrary, at the request
of either Party, the Parties shall meet semi-annually to review proposed
marketing plans for the Product.

                        ARTICLE 4 - BRANDING; TRADEMARKS

     4.1 LICENSE GRANT: BRANDING.  Subject to the terms and conditions of this
Agreement, Valera hereby grants Key an exclusive license to use the Trade Marks
in connection with the marketing, distribution, and sale of the Product in the
Territory for use in the Primary Indication. The Product shall bear a product
name owned by Valera, which product name shall,

                                  CONFIDENTIAL
<PAGE>
                                                                               9

if possible, be the same as the product name used in the United States, as well
as certain other trademarks of Valera and trademarks of Key (other than a
product name of Key) and use the trade dress identified by Valera from time to
time and approved by Key; provided, however, that such labeling shall ensure
that the distinctiveness of the trademarks of each party is maintained and
include a tag line that indicates the ownership of each Party's trademarks.

     4.2 OBLIGATIONS AND CONDITIONS.  No Promotional Materials bearing the Trade
Marks may be used without Valera's prior written approval, which consent shall
not be unreasonably withheld or delayed but shall be conditioned upon
maintaining the distinctiveness of the trademarks of each Party and including a
tag line that indicates Valera's ownership of the Trade Marks. It is agreed by
the Parties that in the event that Valera does not respond to Key's submission
of the new Promotional Materials or labeling within ten (10) Business Days,
consent shall be deemed to be granted. Notwithstanding anything to the contrary,
Key's use of the Trade Marks shall be conditioned upon Key's compliance with
Valera's then-current quality standards, which standards Valera may update from
time to time by written notice to Key, it being understood that Key may use up
any packaging, labeling or Promotional Materials that it has at the time of the
update, either in stock or in process.

     4.3 LICENSE GRANT BY KEY.  Key hereby, for itself and on behalf of its
Affiliates, grants Valera a nonexclusive license to use Key's trademarks, trade
names, logos and trade dress (collectively, the "KEY TRADE MARKS") on labeling
of the Product approved by Key. Notwithstanding anything to the contrary,
Valera's use of the Key Trade Marks shall be conditioned upon Valera's
compliance with Key's then-current quality standards which standards Key may
update from time to time by written notice to Valera, it being understood that
Valera may use up any packaging, labeling or promotional material that it has at
the time of the update, either in stock or in process.

     4.4 CHANGES.  Each Party may discontinue, alter or add new trademarks to be
used in connection with the labeling and marketing of the Product in the
Territory for use in the Primary Indication; provided that: (a) the foregoing
shall not be deemed to allow Key to use or place a product name owned by Key or
licensed by Key from a Third Party on the Product; and (b) each Party may use up
any packaging, labeling or Promotional Materials that it has at the time of the
discontinuance, alteration or addition, either in stock or in process.

     4.5 NO OTHER RIGHTS; ALLOCATION OF GOODWILL.  Except for the licenses
granted by each of Valera and Key to the other under this Agreement, neither
Party shall acquire any right, title, or interest in any trademark, trade name,
logo or trade dress of the other Party by reason of this Agreement. Each of Key
and Valera shall be responsible for registering, as necessary, its own
trademarks, trade names, logos and trade dress. Key acknowledges that all use of
any of Valera's trade names, trademarks, trade dress and logos and all of the
goodwill associated therewith shall inure solely to Valera's benefit. Likewise,
Valera acknowledges that all use of any of Key's trademarks, trade dress, trade
names, and logos, and all of the goodwill associated therewith shall inure
solely to Key's benefit.

     4.6 CONFUSINGLY SIMILAR MARKS.  Key shall not authorize or undertake any
use of any mark that is confusingly similar to the Trade Marks in the Territory.

                                  CONFIDENTIAL
<PAGE>
                                                                              10

     4.7 EFFECT OF TERMINATION.  Upon termination of this Agreement both parties
shall immediately cease all use of the other party's trademarks, trade names,
logos and trade dress, except as set forth in Section 13.7

                       ARTICLE 5 - MANUFACTURE AND SUPPLY

     5.1 MANUFACTURING.  Valera shall, directly or through an Affiliate or Third
Party designee (including contract manufacturers and contract packagers), have
the sole right and responsibility for manufacturing, assembling, packaging and
labeling the Product in such quantities as, in Valera's opinion, are required to
fill all orders and for maintaining such inventory levels of raw materials and
packaging components as are required to meet Key's then- current forecast for
the Product (as delivered pursuant to Section 6.3). Key shall be responsible for
supplying camera-ready proofs of all Labels and other artwork to be included
with the Product.

     5.2 TECHNICAL MANUFACTURING REQUIREMENTS.  In manufacturing the Product,
Valera shall comply with the requirements of Schedule 5.2 applicable to Valera.
If Valera fails to comply with requirements of Schedule 5.2. Key's sole and
exclusive remedy shall be for Valera to replace, at Valera's expense, or at
Key's option, refund or credit the Transfer Fee for, any of the Products
purchased by Key but no longer saleable in the Territory as a direct result of
such failure. Key shall comply with the requirement of Schedule 5.2 applicable
to Key.

     5.3 FAILURE TO SUPPLY.  In the event that Valera or its Affiliates are
unable to supply the Product in specified quality or in quantities sufficient to
meet forecast demand for a successive period of ninety (90) Business Days, then
Key may elect to have the Product made by a Third Party manufacturer designated
by Valera and approved by Key, which approval shall not be unreasonably
withheld, conditioned, denied or delayed. If Key makes such an election, Valera
shall grant the Third Party manufacturer a non-exclusive, royalty-free license
under the Intellectual Property for the sole purpose of manufacturing and
selling to Key the quantity of the Product that Valera is unable to supply.

     5.4 SUPPLY RESUMPTION.  If Key exercises its rights to have a Third Party
manufacturer manufacture the Product pursuant to Section 5.3 and thereafter
during the Term Valera desires to resume supplying Key with the Product (whether
by Valera or otherwise), then Valera shall notify Key of such desire. Key shall
then resume purchasing Product exclusively from Valera for the remainder of the
Term as soon as Valera demonstrates to Key's reasonable satisfaction that Valera
(whether by Valera or otherwise) is capable of re-establishing a satisfactory
supply of the Product; provided that Key shall not be required to cancel any
purchase orders for the Product issued to the Third Party manufacturer that were
issued in accordance with the Forecasts provided to Valera pursuant to Section
6.3 prior to the date that Valera gave Key notice of its desire to resume supply
and cover periods no more than six (6) months after the date that Valera gave
Key notice of its desire to resume supply. If and when Valera resumes supplying
1he Product pursuant to this Section 5.4, the Third Party manufacturer shall be
required to return to Valera all information provided to the Third Party
manufacturer pursuant to Section 5.3 and any license granted to the Third Party
manufacturer shall terminate. Notwithstanding anything in, this Agreement to the
contrary, upon the termination of this Agreement for any reason, the Third Party
manufacturer shall be required to return to Valera all information

                                  CONFIDENTIAL
<PAGE>
                                                                              11

provided to Third Party manufacturer pursuant to Section 5.3 and any license
granted to the Third Party manufacturer shall terminate.

     5.5 DOCUMENTATION AND CERTIFICATE OF ANALYSIS.  Valera shall provide Key
with required supporting documentation for the manufacture and assembly of the
Product in a form suitable for Key's submission to the Regulatory Authorities. A
certificate of analysis and full set of batch manufacturing records shall be
delivered with each batch of the Product delivered to Key.

     5.6 IMPROVEMENTS; NEW FORMULATION.  Valera shall furnish Key with all
information pertinent to the marketing, sale and promotion of the Product
relating to any Improvements, which Valera may make from time to time to the
Product, or to any new formulation of the Product. To the extent reasonably
possible, Valera shall provide Key with six (6) months prior written notice of
any anticipated Improvements or new formulations.

     5.7 EXPIRATION DATE.  The expiration date for the Product will be as
permitted by the applicable Regulatory Approval, provided that Valera
acknowledges that it would be desirable to have expiration dates of at least
twenty-four (24) months.

     5.8 COMPLIANCE WITH LAWS.  Key shall comply with all applicable Laws in
relation to the handling, storage, distribution and sale of the Product in the
Territory and Valera's then- current instructions relating to handling, storage
and shipment of the Products in the Territory.

     5.9 KITS.  Key shall ensure that all components of the Kit have the
necessary regulatory approvals from the Regulatory Authorities to be used,
marketed, distributed and sold in the Territory, and Valera shall give Key
reasonable assistance in this regard at Key's expense (unless otherwise agreed
by Valera in writing). The contents of the Kit may vary from time to time,
subject to mutual written agreement between the Parties and subject to the
condition that Key bears all costs related to any variation of the contents of
the Kit from that listed on Schedule 1.1(p)

              ARTICLE 6 - FORECASTS/ORDERING/TITLE AND RISK/RETURNS

     6.1 ORDERING.  Key may order units of the Product by issuing binding
purchase orders (each, a "PURCHASE ORDER") to Valera pursuant to the terms of
this Agreement. Each Purchase Order shall state the quantity of the product to
be purchased, delivery date(s) and routing instructions, destination or
destinations. No different or additional terms or conditions on any purchase
order, acknowledgment or other transmittal, whether a standard business form or
otherwise, utilized by Key or Valera in connection with the sale of the Product
shall be construed or deemed to be an amendment of or supplement to this
Agreement or otherwise binding on either Key or Valera.

     6.2 ACCEPTANCE OR REJECTION OF PURCHASE ORDERS.  Valera shall indicate its
acceptance or rejection of each Purchase Order within ten (10) Business Days
after receipt; provided that Valera may reject a Purchase Order, in whole or in
part, only if: (a) the Purchase Order fails to comply with the terms and
conditions of this Agreement; (b) the delivery date is less than ninety (90)
days from the date of Valera's receipt of such Purchase Order; or (c) if the
volume under the Purchase Order and all other accepted Purchase Orders covering
the applicable

                                  CONFIDENTIAL
<PAGE>
                                                                              12

monthly period exceeds the volume set forth in Key's then-current forecast
(delivered pursuant to Section 6.3) by more than forty percent (40%). If
requested by Key following Key's receipt of Valera's rejection notice under
clause (c) above, Valera will use commercially reasonable efforts to deliver the
excess volume of the Product specified in the rejected Purchase Order, but
Valera's failure to so deliver the excess volume shall not be a breach of this
Agreement. Valera's sole obligation in filling accepted Purchase Orders shall be
to use commercially reasonable efforts to fill Key's orders for the Product. In
no event shall Valera be liable to any third party for Valera's failure to
deliver the Product to Key by any delivery due date set forth in any Purchase
Order.

     6.3 FORECASTS.  Key shall provide Valera a non-binding twelve (12) month
rolling forecast (the "FORECAST") of Key's estimated requirements of the
Product, itemized for use as commercial product or as samples. The Forecast
shall be reviewed and updated by Key no later than thirty (30) days before the
start of each calendar quarter during the Term. Each such Forecast shall reflect
a good faith attempt by Key to estimate quantity requirements of the Product,
based on anticipated demand therefor.

     6.4 SHIPMENT.  Valera will use diligent efforts to ship the Product ordered
by Key within one hundred and twenty (120) days after its acceptance of Key's
purchase order. The Products will be shipped EXW (Incoterms 2000) to Valera's or
its Third Party designee's facilities. Valera shall ensure that the Product is
suitably packed for shipment in Valera's standard containers.

     6.5 DELIVERY AND ACCEPTANCE.

          6.5.1. ACCEPTANCE.  Key shall not be obliged to accept delivery of any
lot or batch of the Product unless the lot or batch complies with the warranties
set forth in Section 8.1. Each lot or batch of the Product shall be considered
accepted by Key unless Key has rejected the same by delivering written notice
thereof to Valera as soon as is reasonably possible but in any event no later
than thirty (30) days after delivery of such lot or batch of the Product. To the
extent possible, Key shall verify counts and identify any damages to Valera
within five (5) Business Days of receipt. Key's sole and exclusive remedy for
any shortage in a shipment shall be for Valera to send additional units of the
Product as soon as reasonably possible.

          6.5.2. REJECTION NOTICE.  A written notice of rejection shall be
conclusive and binding upon Valera unless Valera notifies Key within forty-five
(45) Business Days after receipt by Valera of the written notice of rejection
that it denies responsibility for the problem in question. In the event of such
a notice by Valera, the claim shall be settled as set forth in Sections 8.3 and
8.4.

          6.6 PRODUCT LIABILITY INSURANCE.  Valera agrees to maintain product
liability insurance consistent with its normal business practices to cover risks
related to the Product and, upon Key's request, to provide Key with certificates
of insurance attesting to the existence of such insurance.

     6.7 ALL RISK INSURANCE.  Key Agrees to maintain all risk and general
liability insurance consistent with its normal business practices to cover risks
related to the storage,

                                  CONFIDENTIAL
<PAGE>
                                                                              13

marketing, sales, and distribution of the Product in the Territory, and, upon
Valera's request, to provide Valera with certificates of insurance attesting to
the existence of such insurance. Valera agrees to maintain all risk and general
liability insurance consistent with its normal business practices to cover
normal business risks and including intellectual property claims, and, upon
Key's request to provide Key with certificates of insurance attesting to the
existence of such insurance. Each Party shall name the other Party as a
co-insured under each insurance policy.

     6.8 INSURANCE NOTIFICATION.  Each Party agrees, upon request, to advise the
other Party of the status of the insurance required by this Article 6 and of any
change in such status. It is understood and agreed that furnishing of such
insurance coverage will not relieve either Party of their obligations under this
Agreement.

     6.9 RETURNS.  Customers of Key may return Product to Key only (a) if the
Product does not comply with the warranties set forth 8.1 or (b) in accordance
with the policy set forth in Schedule 6.9. This policy shall be communicated to
customers in an appropriate fashion. Key shall be responsible for destruction of
the Product returned in accordance with the policy set forth in Schedule 6.9.
Such destruction shall be in accordance with all appropriate Laws relating to
the disposal of pharmaceutical products, including any and all appropriate
environmental Laws.

                      ARTICLE 7 - PRICING AND PAYMENT TERMS

     7.1 PRICING.  Key shall pay Valera for Valera's supply and Key's
distribution of the Product under this Agreement in an amount equal to:

          7.1.1. a transfer fee for each unit of the Product supplied by Valera
to Key under this Agreement (the "TRANSFER FEE"). Until twelve (12) months
following Regulatory Approval, the Transfer Fee shall be USD$250 per unit of the
Product. After twelve (12) months following Regulatory Approval, Valera may
adjust the Transfer Fee once per Calendar Year by giving Key written notice of
the adjusted Transfer Fee, except that no increase shall exceed the aggregate
percentage increase in the Producer Price Index for Drugs and Pharmaceuticals
(Series WPU063), as reported by the Bureau of Labor Statistics of the United
States Department of Labor, during the period since the last price adjustment
(and for which data, preliminary or final, is available); plus

          7.1.2. ten percent (10%) of Net Sales.

     7.2 QUARTERLY REPORT.  Within forty-five (45) days following the end of
each Calendar Quarter, Key shall render a written report to Valera setting forth
the following information and calculations for such Calendar Quarter:

          (a) each component making up Net Sales for the Calendar Quarter and
the calculation of Net Sales;

          (b) the actual number of Product sold (net of returns) for the
Calendar Quarter; and

          (c) the calculation of royalties payable to Valera pursuant to Section
7.1.2.

                                  CONFIDENTIAL
<PAGE>
                                                                              14

     7.3 PHASE IV AND SAMPLE SUPPLIES.  In accordance with Sections 2.4 and 3.8,
Key shall pay Valera for Valera's supply of the Product for use in Phase IV
clinical trials and samples in an amount equal to Valera's fully burdened
manufacturing cost. Key shall pay Valera's invoices for such supplies within
forty-five (45) days after receipt of the Product.

     7.4 PAYMENT.  Key shall pay Valera's invoices for Transfer Fees no later
than sixty (60) days after receipt of each shipment of the Product. Key shall
pay the amounts due under this Agreement no later than forty-five (45) days
following the completion of each Calendar Quarter. All amounts due to Valera in
accordance with the terms hereof shall be paid by cheque or wire transfer in
Dollars to such bank as Valera may direct from time to time. Overdue amounts
shall bear interest at a rate equal to the lower of 1.5% per month or the
highest rate permitted by law from the due date until the date paid. All
expenses incurred by Key in making such transfers shall be borne by Key. To the
extent that Net Sales includes amount collected by Key in currency other than
Dollars, such amounts shall be converted to Dollars using the exchange ratio set
forth in the Wall Street Journal on the last day of the relevant Calendar
Quarter. Unless otherwise agreed by Valera, Key shall obtain a confirmed,
irrevocable letter of credit in favor of Valera in an amount set by Valera from
time to time, against which Valera may draw if Key fails to pay any amount due
under this Agreement. Such letter of credit shall be in form and substance
acceptable to Valera, shall be issued by a bank acceptable to Valera and shall
be payable in Dollars upon presentation of the documentation recited in the
letter of credit.

     7.5 RECORDS.  Key shall record all sales of Product and shall keep full and
true books of account and other records in accordance with the requirements of
generally accepted accounting principles in South Africa and other good business
practice so that details of sales for the Product, the calculation of Net Sales
and Key's payment obligations in respect thereof may be properly ascertained.

     7.6 AUDIT.  Key agrees, at the request of Valera and at Valera's expense,
to permit an independent accounting firm of recognized South African national
standing, selected by Valera to have access, upon reasonable notice, during
ordinary business hours and no more frequently than once in any Calendar Year,
to such books of account and other records as may be necessary to determine the
correctness of any report by Key to Valera in accordance with this Article 7. If
such independent certified public accountant shall determine that an amount is
due and owing by one Party to the other, then the owing Party shall promptly pay
the amount due and owing, provided that if the Party owing the amount is Key and
such amount is five percent (5%) or more of the total amount that should have
been paid to Valera under this Agreement in respect of the audited period, then
Key shall also reimburse Valera for the cost of the audit.

                         ARTICLE 8 - PRODUCT WARRANTIES

     8.1 LIMITED WARRANTY FOR THE PRODUCTS.  Valera warrants to Key that: (a)
each Product will be manufactured and packaged in accordance with GMPs; (b) each
of the Products, when delivered to the carrier, will conform to the
Specifications; and (c) each the Products shall be free from defects in
materials, workmanship, packaging or labeling until the expiration of its stated
shelf life (the "WARRANTY PERIOD").

                                  CONFIDENTIAL
<PAGE>
                                                                              15

     8.2 DISCLAIMER.  THE EXPRESS LIMITED WARRANTY FOR THE PRODUCTS SET FORTH IN
SECTION 8.1 AND THE ADDITIONAL REPRESENTATIONS AND WARRANTIES SET FORTH IN
SECTION 9.1 ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, WHETHER
EXPRESS OR IMPLIED. VALERA HEREBY DISCLAIMS ANY AND ALL OTHER REPRESENTATIONS
AND WARRANTIES OF ANY KIND, EXPRESSED OR IMPLIED, WHETHER ARISING FROM A
COURSE OF DEALING OR USAGE OF TRADE, INCLUDING, WITHOUT LIMITATION, THE IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
NON-INFRINGEMENT.

     8.3 WARRANTY CLAIM PROCEDURE.  Unless otherwise agreed by Valera, to make a
warranty claim, Key shall at Key's expense return the allegedly defective the
Products(s), or a representative sample thereof, together with a description of
the alleged defect. Valera shall, promptly after receipt and as required,
inspect the alleged defective Products(s). If such inspection results reasonably
confirm the Products do not conform with the warranties set forth in Section 8.1
and the non-conformance did not arise from misuse, mishandling, storage in a
manner inconsistent with labeling, neglect, modification or unusual physical or
chemical stress after delivery to the carrier, Key shall return any remaining
the Products(s) in Key's inventory with the same defect at Valera's expense, and
the sole and exclusive warranty remedies set forth in Section 8.4 shall apply.
If such test results fail to confirm the Products' non-conformance to the
warranties set forth in Section 8.1, or if the parties fail to otherwise resolve
the dispute, the parties shall submit the Products, or a representative sample
thereof, along with a reference batch which has previously been shown by Key to
conform to the warranties set forth in Section 8.1, to a mutually acceptable
independent laboratory along with mutually agreeable interrogatories to be
answered by such laboratory. The determination of the Products' conformance or
non-conformance to the warranties set forth in Section 8.1 shall be binding
upon the Parties. If the laboratory determines that the Products conform to the
warranties set forth in Section 8.1, Key shall pay all independent laboratory
and shipping costs incurred by Valera, and if such laboratory confirms that the
Products do not conform with the warranties set forth in Section 8.1, Valera
shall pay all independent laboratory costs and the sole and exclusive warranty
remedies set forth in Section 8.4 shall apply.

     8.4 KEY'S WARRANTY REMEDIES.  During the Warranty Period, Valera shall
replace, at Valera's expense, or at Key's option, refund or credit the Transfer
Fee for, any the Products that do not comply with Valera's limited warranty set
forth in Section 8.1. Valera's obligation to replace defective Product or to
refund or credit the purchase price paid for such the Products pursuant to this
Section 8.4 shall not apply to any Product that has been subjected to misuse,
mishandling, storage in a manner inconsistent with labeling, neglect,
modification or unusual physical or chemical stress after delivery to the
carrier. Other than with respect to third party claims for which Valera must
indemnify Key pursuant to Section 10.2, this Section 8.4 states Key's sole and
exclusive remedy for failure of any the Products to comply with the limited
warranties set forth in Section 8.1.

              ARTICLE 9 - REPRESENTATIONS AND ADDITIONAL WARRANTIES

     9.1 REPRESENTATIONS AND WARRANTIES OF VALERA.  Valera hereby makes the
following representations and warranties to Key and does so in full
understanding and acknowledgement

                                  CONFIDENTIAL
<PAGE>
                                                                              16

that Key is relying on such representations and warranties in entering into
this Agreement, notwithstanding any due diligence investigation done or
information obtained by Key prior to the Effective Date:

          (a) STATUS.  Valera is a corporation organized and existing under the
Laws of the State of Delaware, U.S.A. No action has been taken by the directors,
officers or shareholders of Valera to dissolve the corporation. Valera has the
corporate power and authority to enter into this Agreement and to perform all
its obligations under this Agreement.

          (b) ALL NECESSARY PROCEEDINGS.  The execution and delivery by Valera
of this Agreement, the performance by Valera of all the terms and conditions
thereof to be performed by it and the consummation of the transactions
contemplated hereby have been duly authorized by all necessary corporate actions
and proceedings, and no other act or approval of any Person is required to
authorize such execution, delivery, and performance.

          (c) NO VIOLATION.  The execution, delivery and performance of this
Agreement by it: (i) does not violate or conflict with any provision of Law or
any provision of its articles of incorporation or by-laws; and (ii) does not and
will not, with or without the passage of time or the giving of notice, result in
the breach of, or constitute a default, cause the acceleration of performance,
or require any consent under, or result in the creation of any lien, charge or
encumbrance upon any of its property or assets pursuant to any material
instrument or agreement to which it is a party or by which it or its properties
may be bound or affected. Without limiting the generality of the foregoing,
Valera has not made any written or oral agreement or undertaking with any other
Person regarding the rights to promote, distribute or sell the Product or to
seek Regulatory Approval for the Product in the Territory.

          (d) THIRD PARTY CLAIMS.  To Valera's knowledge, as of the Effective
Date, there is no outstanding or threatened claim or allegation that the
marketing, distribution or sale of the Product or use of the Trade Marks in
accordance with this Agreement infringe upon any rights of a Third Party in the
Territory.

          (e) RIGHT TO GRANT LICENSES.  To Valera's knowledge, Valera is the
sole and exclusive owner or licensee of all Intellectual Property needed to
market, distribute and sell the Product in the Territory in accordance with this
Agreement. Valera has the full right, power and authority to grant the rights
granted to Key under this Agreement, free and clear of any mortgage, lien or
encumbrance.

          (f) REGULATORY APPROVAL.  As of the Effective Date of this Agreement,
Valera is not aware of any facts that would reasonably lead it to conclude that
the Product will be unable to receive Regulatory Approval in the Territory.

                                  CONFIDENTIAL
<PAGE>
                                                                              17

     9.2 REPRESENTATIONS AND WARRANTIES OF KEY.  Key hereby makes the following
representations and warranties to Valera and does so in full understanding and
acknowledgement that Valera is relying on its said representations and
warranties in entering into this Agreement, notwithstanding any due diligence
investigation done or information obtained by Valera prior to the Effective
Date:

          (a) STATUS.  Key is a limited company organized and existing under the
Laws of South Africa. No action has been taken by the directors, officers or
shareholders of Key to dissolve the corporation. Key has the corporate power and
authority to enter into the present Agreement and to perform all its obligations
hereunder.

          (b) ALL NECESSARY PROCEEDINGS.  The execution and delivery by Key of
this Agreement, the performance by Key of all the terms and conditions thereof
to be performed by it and the consummation of the transactions contemplated
hereby have been duly authorized by all necessary corporate actions and
proceedings, and no other act or approval of any Person is required to authorize
such execution, delivery, and performance.

          (c) NO VIOLATION.  Key warrants that the execution, delivery and
performance of this Agreement by it: (i) does not violate or conflict with any
provision of Law or any provision of its articles of incorporation or by-laws;
and (ii) does not and will not, with or without the passage of time or the
giving of notice, result in the breach of, or constitute a default, cause the
acceleration of performance, or require any consent under, or result in the
creation of any lien, charge or encumbrance upon any of its property or assets
pursuant to any material instrument or agreement to which it is a party or by
which it or its properties may be bound or affected.

     9.3 LIMITS ON REPRESENTATIONS AND WARRANTIES.  Nothing in this Agreement
shall be construed as a representation or warranty by Key that it will be
successful in obtaining Regulatory Approval for the Product for the Primary
Indication.

                          ARTICLE 10 - INDEMNIFICATION

     10.1 BY KEY.  Key shall indemnify Valera, its affiliates and their
respective directors, officers, shareholders, employees or agents (collectively,
the "VALERA RELEASEES"), and hold it harmless from and against any and all
losses (including personal injury, death or property damage) arising from any
and all Third Party claims against the Valera Releasees: (a) relating to the
marketing, distribution or sale of the Product in the Territory to the extent
such claims are the result of the fault, negligence or willful misconduct of
Key, or its Affiliates, or their respective directors, officers, shareholders,
employees or agents; (b) of any nature whatsoever relating to any processing or
repackaging of the Product after delivery to the carrier in accordance with
Section 6.4; or (c) caused by a breach or misstatement by Key of its
representations and warranties under this Agreement; except to the extent such
Third Party claims result from the fault, negligence or willful misconduct of
the Valera Releasees or its or their material failure to comply with the terms
of this Agreement. Key shall not be liable under this section 10.1 In the event
that the Valera Releasees admit or settle any such claim without the prior
written consent of Key, which consent shall not be unreasonably withheld,
conditioned, delayed or denied.

                                  CONFIDENTIAL
<PAGE>
                                                                              18

     10.2 BY VALERA.  Valera shall indemnify Key, its Affiliates and their
respective directors, officers, shareholders, employees or agents (collectively,
the "KEY RELEASEES"), and hold it harmless from and against any and all Losses
(including personal injury, death or property damage) arising from any and all
Third Party claims against the Key Releasees: (a) that the manufacture, use or
sale of the Product in accordance with this Agreement infringes the intellectual
property rights of a third party in the Territory; (b) of any nature whatsoever
relating to the manufacture or use of the Product; or (c) caused by a breach or
misstatement by Valera of its representations and warranties in Section 9.1;
except to the extent such Third Party claims result from the fault or negligence
of the Key Releasees, or its or their material failure to comply with the terms
of this Agreement. Valera shall not be liable under this Section 10.2 in the
event that the Key Releasees admit or settle any such claim without the prior
written consent of Valera, which consent shall not be unreasonably withheld,
delayed or denied.

     10.3 INDEMNIFICATION PROCEDURE.  A Party seeking indemnification (the
"INDEMNIFIED PARTY") shall notify, in writing, the other Party (the
"INDEMNIFYING PARTY") within fifteen (15) Business Days after the assertion of
any claim or discovery of any fact upon which the Indemnified Party intends to
base a claim for indemnification. An Indemnified Party's failure to so notify
the Indemnifying Party shall not, however, relieve such Indemnifying Party from
any liability under this Agreement to the Indemnified Party with respect to such
claim except to the extent that such Indemnifying Party is actually denied,
during the period of delay in notice, the opportunity to remedy or otherwise
mitigate the event or activity (ies) giving rise to the claim for
indemnification and thereby suffers or otherwise incurs additional liquidated or
other readily quantifiable damages as a result of such failure.

     10.4 DEFENDING CLAIMS.  The Indemnifying Party, while reserving the right
to contest its obligations to indemnify the Indemnified Party under this
Agreement, shall be responsible for the defense of any claim, demand, lawsuit or
other proceeding in connection with which the Indemnified Party claims
indemnification hereunder. The Indemnified Party shall have the right, at its
expense, to participate jointly with the Indemnifying Party in the defense of
any such claim, demand, lawsuit or other proceeding, but with respect to any
issue involved in such claim, demand, lawsuit or other proceeding with respect
to which the Indemnifying Party has acknowledged its obligation hereunder, the
Indemnifying Party shall have the right to select counsel, settle, try or
otherwise dispose of or handle such claim, demand, lawsuit or other proceeding
on such terms as the Indemnifying Party shall deem appropriate, subject to any
reasonable written objection of the Indemnified Party.

                   ARTICLE 11 - INTELLECTUAL PROPERTY MATTERS

     11.1 INTELLECTUAL PROPERTY INFRINGEMENT.

          11.1.1. Without limiting the obligations and requirements of Sections
10.2 through 10.4, each Party will notify the other Party if it receives any
notice that the activities engaged in under this Agreement infringe or may
infringe any Third Party's intellectual property rights. If Key establishes to
Valera's reasonable satisfaction that license(s) under such Third Party's
intellectual property rights is necessary or advisable for purposes of enabling
Key to market, use or sell the Products in the Territory, Valera and Key shall
co-operate to obtain such license(s) for the benefit of Valera and Key, in
accordance with the following provisions:

                                  CONFIDENTIAL
<PAGE>
                                                                              19

          11.1.2. Valera shall be primarily responsible for obtaining any such
third party license. The matter shall be deemed resolved if Valera is granted a
license, whether royalty-free or royalty-bearing, under the relevant
intellectual property rights that would make the continued marketing, use or
sale of the Products in the Territory for use in the Primary Indication non-
infringing with respect to such Third Party's intellectual property rights.

          11.1.3. However, in the event that Valera is unable to resolve the
matter in accordance with Section 11.1.2 in spite of good faith efforts and/or
upon terms that are commercially reasonable to Valera, then Key shall be
entitled to negotiate a license in favor of Key under such Third Party's
intellectual property rights, provided that Key shall not enter into such
license without the prior written consent of Valera, such consent not to be
unreasonably withheld or delayed. In the event that such license requires Key to
pay the Third Party royalties, Key may deduct such royalties from the amounts
due to Valera under Section 7.1.2, not to exceed an amount equal to two percent
(2%) of Net Sales during the applicable Calendar Quarter.

          11.1.4. Should any claim or suit that the Product infringes any Third
Party's intellectual property rights in the Territory be upheld by a final,
non-appealable order of a court such that Key is prevented from marketing, using
and selling the Product in the Territory and no license that permits Key to
market, use and sell the Product in the Territory in accordance with this
Agreement is obtained by either Valera or Key pursuant to Sections 11.1.2 and
11.1.3, Valera shall repurchase from Key, at cost, all of the Product currently
in Key's stock that have not been sold and, if commercially reasonable to
Valera, change the Product so as to make it non-infringing. If changing the
Product so as to make it non-infringing is not commercially reasonable to
Valera, Valera may terminate this Agreement effective upon giving Key notice of
termination.

     11.2 THIRD PARTY INFRINGEMENT.

          11.2.1. In the event that either Party determines that a Third Party
(other than a permitted licensee, transferee or distributor of either Party) is
making, using, or selling a product or process that may infringe any of the
Intellectual Property relating to the Product, including later issued and
acquired patents covering the Product, or any uses or processes pertaining
thereto, it will promptly notify the other Party in writing.

          11.2.2. Valera shall be responsible for, in its sole discretion,
obtaining a discontinuance of any infringement or bringing suit against a Third
Party infringer relating to the Product. Notwithstanding anything contained
herein to the contrary, Valera shall have the right, but not the obligation, to
bring such a suit. Valera shall bear all the expenses of any such suit brought
by it and shall, after retaining for itself an amount equal to such expenses,
split equally the remaining balance of any and all recovery and damages
therefrom with Key. Key agrees to be named as a co-plaintiff if Valera brings
suit and shall cooperate with Valera (which shall include providing any
necessary assistance and executing any necessary documents, with any reasonable,
receipted out-of-pocket expenses being reimbursed to Key by Valera to the extent
such expenses were previously approved in writing by Valera), and shall have the
right to consult with Valera and to participate in and be represented by
independent counsel in such litigation at its own expense. Except as otherwise
specifically provided herein, Valera shall have control

                                  CONFIDENTIAL
<PAGE>
                                                                              20

over any such suit, and decisions as to settlement, methods and/or terms and
conditions for resolving the suit shall be made by Valera (after consultation
with Key, should Key be joined as a party to such suit).

          11.2.3. In the event Valera chooses not to prosecute an infringement
as aforesaid within ninety (90) days after learning of the infringement, Key
shall have the right to do so. In such event, Valera shall cooperate with Key
(which shall include providing any necessary assistance and executing any
necessary documents, with any reasonable, receipted out-of-pocket expenses being
reimbursed to Valera by Key to the extent such expenses were previously approved
in writing by Key). Key shall bear all the expenses of any such suit brought by
it and shall, after retaining for itself an amount equal to such expenses, split
equally the remaining balance of any and all recovery and damages from such suit
with Valera. No settlement, consent judgment or other voluntary final
disposition of the suit may be entered into without the prior written consent of
Valera.

                          ARTICLE 12 - CONFIDENTIALITY

     12.1 CONFIDENTIAL INFORMATION.  For the purposes of this Agreement,
"CONFIDENTIAL INFORMATION" means all verbal, written, electronically transmitted
and/or machine reproduced information, chemical structures, data, documents,
methods and Intellectual Property of or relating to the business of either Party
or its Affiliates, already provided or disclosed by it or its Affiliates to the
other Party, or which will be provided to the other Party under this Agreement,
and all materials, data, results, reports and other documents generated by or on
behalf of the other Party containing or regarding such information, data,
documents, methods and Intellectual Property.

     12.2 OBLIGATIONS.  During the Term, each Party may supply to the other
Party such Confidential Information as is considered useful solely for the
purpose of enabling the other Party to perform its obligations hereunder (the
"PURPOSE"). The other Party shall not use or allow the use of the Confidential
Information for any purpose other than the Purpose or to enforce its rights
under this Agreement.

     12.3 EXCEPTIONS.  Neither Party shall have any obligation of non-disclosure
or non-use hereunder with respect to any Confidential Information which:

          (a) at the time of disclosure to the other Party is already available
or known to the public;

          (b) after disclosure to the other Party becomes available or known to
the public through no breach of this Agreement;

          (c) is already lawfully in the possession of the other Party at the
time disclosure hereunder was made and such possession is documented by written
evidence and not subject to any obligation of non-disclosure or non-use; or

          (d) is received from a Third Party having the right to disclose same
and who is not bound by obligations of non-disclosure and/or non-use.

                                  CONFIDENTIAL
<PAGE>
                                                                              21

     12.4 COMPELLED DISCLOSURE.  If a Party shall become compelled by any
requirement of law or pursuant to any legal, regulatory or investigatory
proceeding before any court, tribunal or other governmental entity, agency or
commission to disclose Confidential Information of the other Party, such Party
shall give the other Party prompt written notice of its receipt of the order or
notice requiring the disclosure so that the other Party may seek a protective
order or other remedy to protect the confidentiality of the Confidential
Information and/or waive the compelled Party's obligations under this Article
12. If such protective order, other remedy or waiver is not obtained or granted
by the time the compelled Party is required to comply, the compelled Party may
furnish only that portion of the Confidential Information of the disclosing
Party that it is compelled to disclose and no more.

     12.5 UNAUTHORISED USE.  In case either Party becomes aware or has knowledge
of any unauthorised use or disclosure of Confidential Information, it shall
promptly notify the other Party of such unauthorised use or disclosure and,
thereafter, shall take all reasonable steps to assist the other Party in
attempting to minimise any potential or actual damages or losses resulting from
such unauthorised use or disclosure.

     12.6 RETURN OF DOCUMENTS.  Each Party, upon receipt of a written request
from the other Party following the expiration or termination of this Agreement,
shall promptly return to the other Party all Confidential Information of such
other Party, including all reproductions and copies thereof together with all
internal material and documents generated by it containing Confidential
Information or references thereto or from which references the substance of the
Confidential Information can be implied or understood and shall delete all
references thereto stored electronically.

     12.7 OWNERSHIP RIGHTS.  Each Party agrees that it shall not claim to have
any rights, title or ownership in the Confidential Information of the other
Party or any discoveries or inventions based on or derived from the Confidential
Information, and that rights, title and ownership in the Confidential
Information or any discoveries or inventions based on or derived from said
Confidential Information shall, as between the Parties, rest in the disclosing
Party. Each party agrees to promptly disclose to the disclosing Party any
discoveries or inventions based on or derived from the Confidential Information.
Each Party further agrees to assign (and does hereby assign) to the disclosing
Party, the sole and exclusive ownership in all such discoveries and inventions
and to sign all documents and do all things required to give effect thereto.

     12.8 TERM.  The provisions of this Article 12 shall survive the expiration
or termination of the Agreement until all of the Confidential Information has
fallen within one of the exceptions set forth in Sections 12.3.

                        ARTICLE 13 - TERM AND TERMINATION

     13.1 TERM.  This Agreement shall commence upon the Effective Date and shall
continue until the fifth (5th) anniversary of the date on which Regulatory
Approval is obtained for the Primary Indication unless sooner terminated as
provided elsewhere in this Agreement. This Agreement shall automatically renew
for additional periods of one (1) year each unless a Party

                                  CONFIDENTIAL
<PAGE>
                                                                              22

gives notice to the other Party at least six (6) months prior to the completion
of the then-current term.

     13.2 TERMINATION.  This Agreement may be terminated:

          (a) By a Party if the other Party commits a Material Breach of any of
its obligations under this Agreement and (i) fails to remedy the breach within
thirty (30) Business Days of being required by the first Party to do so; or (ii)
where remedy of the breach is not reasonably possible within thirty (30)
Business Days, fails to propose a plan within twenty (20) Business Days which,
in the opinion of the first Party acting reasonably, is capable of providing a
remedy of the breach within ninety (90) Business Days.

          (b) If either Party shall commence as debtor any proceedings under any
bankruptcy, insolvency, readjustment of debt, dissolution or liquidation Law or
any such proceeding shall be commenced against either Party, or any trustee or
receiver shall be appointed therefor, and either Party shall by any act or
failure to act indicate approval of or consent to, or acquiescence in such
proceedings or in the appointment of any such trustee or receiver; or if any
such proceedings brought against either Party shall be approved by any court and
shall remain undismissed for thirty (30) Business Days after its levy, then in
any such case, the Party not involved in such proceedings shall have the option
to terminate this Agreement in its entirety by written notice of such
termination to the Party involved in such proceedings and upon the giving of
such notice this Agreement shall immediately terminate.

          (c) By either Party, upon at least thirty (30) days prior written
notice to the other Party, if, as a result of an Event of Force Majeure, the
other Party is unable to fully perform its obligations hereunder for a period of
one hundred fifty (150) consecutive days; provided that if the required
performance is met during the thirty (30) day period, this Agreement shall
continue in full force and effect as if the notice had not been given.

          (d) By a Party, if any Regulatory Authority has finally denied
Regulatory Approval (or any material part thereof) for the Product with respect
to the Primary Indication.

     13.3 PARTIAL TERMINATION.  In the event that any termination of this
Agreement is limited to one (1) or more, but not all forms or dosages of the
Product, then the effects of such termination shall only apply to the affected
form(s) or dosage(s), but shall not affect in any way the validity of this
Agreement with respect to any other form or dosage.

     13.4 REMEDIES NOT LIMITED.  The termination of this Agreement by either
Party shall not limit remedies that may be otherwise available.

     13.5 SURVIVAL.  Expiration or termination of this Agreement for any reason
shall not relieve either party of its obligations that have accrued prior to the
expiration or termination of this Agreement. Without limiting the generality of
the foregoing, Article 1, Article 7, Article 8, Article 10, Article 12 and
Article 15 and Sections 3.3,3.5, 4.5,4.6, 4.7,11.1,13.4,13.5,13.6 and 13.7 shall
survive expiration or termination of this Agreement for any reason.

     13.6 POST-TERMINATION.  Unless Valera terminates this Agreement pursuant to
Sections 13.2(a) or 13.2(b), during a six (6) month period following the
expiration or termination

                                  CONFIDENTIAL
<PAGE>
                                                                              23

of this Agreement, Key may sell out its stock on hand of the Product. All
applicable provisions of this Agreement shall survive termination as necessary
to give effect to this Section 13.6.

     13.7 OTHER CONSEQUENCES OF TERMINATION.  Upon termination or expiration of
this Agreement, Key shall within thirty (30) days from the date of receipt of a
request from Valera submit all necessary paperwork to all Regulatory Authorities
to request assignment of the NDA and all related registrations and product
numbers for the Product and any other Regulatory Approval held with respect to
the Product (in each case to the extent in Key's name), provided that Valera
shall pay to Key an amount sufficient to cover any costs incurred by Key in
connection with obtaining Regulatory Approval for the Product and transferring
same back to Valera.

                           ARTICLE 14 - FORCE MAJEURE

     14.1 DEFINITION.  For the purposes of this Agreement, an "EVENT OF FORCE
MAJEURE" means any one or more of the following:

          (a) acts of God;

          (b) expropriation, confiscation or requisitioning of facilities or
compliance with any Law which affects to a degree not presently existing the
supply, availability or use of materials or labour;

          (c) acts or inaction on the part of any Governmental Body or Person
purporting to act therefor;

          (d) embargoes, or acts of war or the public enemy, whether war be
declared or not;

          (e) strikes, public disorder, insurrection, rebellion, riots or
violent demonstrations;

          (f) floods, earthquakes, lightning, hail, inclement weather conditions
or other natural calamities; and

          (g) any circumstances whether or not of the class or kind specifically
named above not within the reasonable control of a Party and which, despite the
exercise of reasonable diligence, such Party is unable to prevent, avoid or
remove.

     14.2 PROCEDURE.  If any Party wishes to invoke an Event of Force Majeure,
then it shall (i) promptly following the commencement of such Event of Force
Majeure notify the other Parties of the occurrence of such event of Force
Majeure, the reasonably estimated date and time on which it commenced and the
nature of the Event of Force Majeure, and (ii) as soon as reasonably practicable
thereafter, submit to the other Parties proof of the Event of Force Majeure.

     14.3 SUSPENSION OF OBLIGATIONS.  If one of the Parties is unable to perform
its obligations under this Agreement because of an Event of Force Majeure, then
such Party shall be

                                  CONFIDENTIAL
<PAGE>
                                                                              24

excused from performance of its obligations under this Agreement until the Event
of Force Majeure terminates and the obligations of such Party, which cannot be
met due to the Event of Force Majeure, shall be suspended during the pendency of
the Event of Force Majeure, provided that such Party uses all reasonable efforts
to attempt to prevent, avoid or remove the Event of Force Majeure within the
shortest possible delay. Nevertheless, an Event of Force Majeure has no effect
on the obligation to pay a sum of money owing for the purchase of the Product.

     14.4 RESOLUTION.  If either Party is excused from performance under this
Agreement because of an Event of Force Majeure, then the Parties agree to
promptly meet and to work in good faith together in an attempt to find
appropriate solutions and to shorten the duration of the Event of Force Majeure,
to the extent reasonably feasible.

                           ARTICLE 15 - MISCELLANEOUS

     15.1 LIMITATIONS OF LIABILITY.  EXCEPT IN RESPECT OF VALERA'S
INDEMNIFICATION OBLIGATIONS UNDER THIS AGREEMENT, IN NO EVENT SHALL VALERA'S
LIABILITY TO KEY FOR DAMAGES UNDER OR IN RESPECT OF THIS AGREEMENT EXCEED, IN
THE AGGREGATE, THE TOTAL AMOUNT PAID TO VALERA UNDER THIS AGREEMENT DURING THE
TWELVE (12) MONTHS PRECEDING THE EVENT GIVING RISE TO THE DAMAGE, WHETHER SUCH
DAMAGES ARISE IN TORT, CONTRACT OR OTHERWISE. IN ADDITION, IN NO EVENT SHALL
VALERA BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES,
HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY. THIS LIMITATION WILL APPLY EVEN
IF VALERA HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

     15.2 NOTICES.  Any notice or other communication required or permitted to
be given hereunder shall be in writing and shall be delivered in person,
transmitted by facsimile or sent by internationally-recognized overnight courier
mail, charges prepaid, addressed as follows:

          (a)  if to Valera:

               Valera Pharmaceuticals, Inc.
               8 Clarke Drive
               Cranbury, New Jersey 08512-3617
               U.S.A.
               Attention: President

               Telephone: 609-409-9010
               Fax: 609-409-1650

          (b)  if to Key:

                                  CONFIDENTIAL
<PAGE>
                                                                              25

               Key Oncologies (Pty) Ltd
               171 Katherine Road, Building 1
               Sandton
               South Africa
               Attention: President

               Telephone: + 27 - 11 - 444 - 9440
               Fax: + 27 - 11 - 444 - 9441

          Any such notice or other communication shall be deemed to have been
          given and received on the day on which it was delivered or
          successfully transmitted (or, if such day is not a Business Day, on
          the next following Business Day) or, if sent by
          internationally-recognized overnight courier, on the date on which it
          was received or refused delivery. Either Party may change its address
          for service from time to time by giving notice thereof to the other
          Party in accordance with this Article.

     15.3 AMENDMENTS.  No amendment or waiver shall be binding on either Party
unless consented to in writing by such Party. No waiver of any provision of this
Agreement shall constitute a waiver of any other provision, nor shall any waiver
constitute a continuing waiver unless otherwise expressly provided.

     15.4 DISPUTE RESOLUTION.  Any dispute, controversy or claim arising out of
or relating to this Agreement including any question regarding its existence,
interpretation, validity, breach or termination shall be referred to and finally
resolved by arbitration under the International Arbitration Rules of ADR
Chambers International ("ACI). Any arbitration commenced pursuant to this clause
shall be administered by ACI and its then-current administrative procedures and
schedule of costs will apply. Such arbitration proceeding shall be conducted in
London, England, in person and in the English language applying the laws of the
United States of America and of the State of New Jersey, without giving effect
to the conflict or choice of laws principles of New Jersey or any other
jurisdiction, and in such an expedited manner as is then permitted by ACI's
rules. The agreement to arbitrate all disputes and the results, determinations,
findings, judgments and awards rendered through such arbitration shall be final,
non-appealable and legally binding on the parties to this Agreement and may be
entered and enforced by any court or tribunal of competent jurisdiction. Any
arbitration proceeding shall be initiated by written notice from any party to
the other party. The arbitration shall be conducted before a panel of one (1)
arbitrator appointed by ACI. Time is of the essence of this arbitration
procedure, and the arbitrator shall be required to render its decision within
thirty (30) days after the arbitration's completion. The cost of the arbitration
(including, without limitation, reasonable attorneys' fees, expenses and
disbursements) shall be borne as the arbitrator shall decide; otherwise such
costs (including, without limitation, the prevailing party's reasonable
attorneys' and accountants' fees, expenses and disbursements) shall be borne by
the party against which the award of the arbitrator is to be enforced.

     15.5 ASSIGNMENT.  The rights and obligations under this Agreement may not
be assigned by Key (except to an Affiliate) without the prior written consent of
Valera, which consent shall not be unreasonably withheld or delayed. Valera may
assign its rights under this Agreement in its sole discretion.

                                  CONFIDENTIAL
<PAGE>
                                                                              26

     15.6 FURTHER ASSURANCES.  Each Party will, from time to time subsequent to
the date hereof, at the request and expense of any other Party, execute and
deliver all such documents and do all such other acts and things as that other
Party, acting reasonably, may from time to time request be executed or done in
order to better evidence or perfect or effectuate any provision of this
Agreement or any of the respective obligations intended to be created hereby or
thereby.

     15.7 PUBLICITY.  Neither Party shall issue any press release or other
public announcement relating to existence or terms of this Agreement without the
prior written consent of the other Party (which consent shall not be
unreasonably withheld or delayed), except where such announcements are required
by law or regulation, in which event the Parties will use all reasonable efforts
to consult with each other and co-operate with respect to the wording of any
such announcement. The Parties shall cooperate in issuing (an) initial public
release(s) with respect to the signing of this Agreement, either separately or
as a joint release.

     15.8 COUNTERPARTS.  This Agreement may be executed in counterparts, each of
which shall constitute an original and all of which taken together shall
constitute one and the same instrument in effect as of the date first above
mentioned.

     15.9 GOVERNING LAW.  This Agreement shall be governed by and interpreted in
accordance with the Laws in effect in the State of New Jersey, U.S.A.
applicable to contracts entered into by residents of New Jersey and wholly
performed within New Jersey.

     15.10 LANGUAGE.  The Parties confirm that it is their wish that this
Agreement as well as all other documents relating to this Agreement, including
notices, have been and shall be drawn up in the English language only.

     15.11 ENTIRE AGREEMENT.  This Agreement constitutes the entire agreement
between the Parties with respect to the subject matter of this Agreement and
supersede all prior and contemporaneous agreements, understandings, letters of
intent, negotiations and discussions, whether written or oral. There are no
conditions, covenants, agreements, representations, warranties or other
provisions, express or implied, collateral, statutory or otherwise, relating to
the subject matter of this Agreement, except as provided in this Agreement. This
Agreement shall not be changed or modified except in writing.

                            (SIGNATURE PAGE FOLLOWS)

                                  CONFIDENTIAL
<PAGE>
     IN WITNESS WHEREOF, this Agreement has been executed by the Parties on the
date first set forth above.

VALERA PHARMACEUTICALS, INC.

By: /s/ David S. Tierney                Date: 9/17/03
    ---------------------------------
Name: David S. Tierney
Title: President & CEO

KEY ONCOLOGICS (PTY) LTD

By: /s/ Magriet de Wet                  Date: 9/26/03
    ---------------------------------
Name: Magriet de Wet
Title: MANAGING DIRECTOR

                                  CONFIDENTIAL
<PAGE>
                                 SCHEDULE 1.1(N)
                   TO THE LICENSE AND DISTRIBUTION AGREEMENT
                                     BETWEEN
                          VALERA PHARMACEUTICALS, INC.
                                       AND
                            KEY ONCOLOGICS (PTY) LTD

                         CURRENT IMPLANT SPECIFICATIONS

Trade name:        Hydron Implant(TM)

Active Ingredient: Histrelin acetate

Form:              All dosage strengths and forms as well as all Improvements
                   (as defined in Section 1.1(o)).

                                  CONFIDENTIAL
<PAGE>
                                 SCHEDULE 1.1(P)
                   TO THE LICENSE AND DISTRIBUTION AGREEMENT
                                     BETWEEN
                          VALERA PHARMACEUTICALS, INC.
                                       AND
                            KEY ONCOLOGICS (PTY) LTD

                                 CONTENTS OF KIT

The Kit shall include the following components:

     -    Device to insert the Implant

     -    25g x 1.5" Needles

     -    18g x 1" Needles

     -    Gauze Sponges 4"

     -    Elastoplast

     -    Adson Forcep 4.75"

     -    Disposable Scalpels

The following components may be included in the Kit after mutual written
agreement between the Parties:

     -    Poly lined towel Fenestrated Sterile Field

                                  CONFIDENTIAL
<PAGE>
                                SCHEDULE 1.1(FF)
                   TO THE LICENSE AND DISTRIBUTION AGREEMENT
                                     BETWEEN
                          VALERA PHARMACEUTICALS, INC.
                                       AND
                            KEY ONCOLOGICS (PTY) LTD

                             PRODUCT SPECIFICATIONS

  TO BE ATTACHED SUBSEQUENT TO THE EFFECTIVE DATE PURSUANT TO SECTION 1.1(FF)

                               KIT SPECIFICATIONS

   TO BE ATTACHED SUBSEQUENT TO THE EFFECTIVE DATE PURSUANT TO SECTION 1.1(FF)

                                  CONFIDENTIAL
<PAGE>
                                  SCHEDULE 5.2
                   TO THE LICENSE AND DISTRIBUTION AGREEMENT
                                     BETWEEN
                          VALERA PHARMACEUTICALS, INC.
                                       AND
                            KEY ONCOLOGICS (PTY) LTD

1. DOCUMENTATION. Valera shall maintain master documentation for the master
formula, raw material specifications and testing procedures, manufacturing
specifications, in- process testing specifications, packaging component
(printed) specifications, packaging component (unprinted) specifications and
final product specifications and testing procedures that complies with the
requirements of the MBRl for the Product (the "Master Documentation"). Key shall
have the right to review such master documentation prior to its finalization,
and Valera shall make the changes to such master documentation reasonably
requested by Key and directed to causing such master documentation to comply
with the MBRl.

2. MBRl and cGMP. Valera shall manufacture the Product in compliance with the
quantitative formula, procedures, analytical methods and specifications
established and registered in the MBRl and in compliance with GMPs.

3. RAW MATERIALS; PRINTED AND UNPRINTED PACKAGING MATERIALS.

     Valera shall:

     3.1 ensure that all inactive raw materials (RM's) are obtained from the
suppliers listed in the MBR1;

     3.2 ensure that at least description and identification tests are
performed on these inactive RMs if such tests are required by the MBRl and the
results of such tests do not appear on the certificate of analysis ("COA") for
the inactive RMs and maintain records of the results of such tests for at least
three (3) years or if longer, the period required by applicable Law;

     3.3 ensure that active RM's as per annexure 2 of the MBRl are purchased
from the manufacturer/supplier/broker listed in the MBRl, are tested to
specification, that the test results are within limits and indicated as such on
the COA from the manufacturer/supplier/broker;

     3.4 ensure that in the event that the manufacturer's/supplier's/broker's
COA are accepted for any active RM, at least identification and assay tests have
been performed. The results of such tests shall be maintained for a period of at
least three (3) years, or if longer, the period required by applicable Law;

     3.5 ensure that the analytical and test methods for the RMs are followed
according to those laid down in the MBRl and that the results of such tests are
maintained for a period of three (3) years or if longer, the period required by
applicable Law;

     3.6 ensure that all packaging components are purchased from
manufacturers/suppliers/brokers listed in the MBRl and to the extent required by
the MBRl, said components are tested to specification as per annexure 9 of the
MBRl. Valera shall

                                  CONFIDENTIAL
<PAGE>
maintain the results of such tests for a period of three (3) years or if longer,
the period required by applicable Law; and

     3.7 maintain a current "Standard Reference File" containing approved
specimens of each packaging component, to be used as a reference standard in
quality control and release of packaging components to ensure that packaging
components (printed and unprinted) are in compliance with specifications as in
the MBR1. Key must approve all printing component proofs prior to orders being
placed for same.

4. MANUFACTURING. Valera shall:

     4.1 manufacture the Product according to the current Master Documentation
and GMPs;

     4.2 ensure that all weighing of RM's will be re-checked and ensure that all
additions of RM's (whether active or inactive) during manufacture will be
verified;

     4.3 ensure that all in-process testing will be done as specified in the
Master Documentation and documented in the associated Batch Manufacturing Record
(BMR);

     4.4 ensure that all testing of the Product will be done at the approved
facility according to the MBR1;

     4.5 ensure that all test results required prior to packing the Product in
bulk, as well as all in-process testing results, are performed prior to packing
the Product in bulk;

     4.6 promptly report to Key regarding any deviations from the manufacturing
process specified in the Master Documentation. Such deviations will be fully
documented in the associated BMRs; and

     4.7 inform Key in writing of any proposed changes to the Master
Documentation. Written approval will be obtained from Key before implementing
any of such changes by Valera, which approval shall not be withheld or delayed,
provided that no such approval from Key shall be required if such proposed
change is a result of changes in GMPs or changes required by the Regulatory
Authorities in the United States which changes effect the manufacturing,
packaging, testing, quality control, quality assurance and other processes
applicable to the Product marketed and sold in the United States.

5. PACKAGING. Valera shall:

     5.1 perform all packaging according to the Master Documentation and MBR1;

     5.2 place the orders for all printed packaging materials and perform the
related quality control checks of same according to the Master Documentation;

     5.3 record batch numbers of all components to ensure traceability;

                                  CONFIDENTIAL
<PAGE>
     5.4 perform reconciliations on packaging materials and store the
documentation for such reconciliation with the related BMR;

     5.5 ensure that a formal documented opening of the packaging line is
performed which at least includes:

          -    approval of bulk for packaging

          -    correctness of packaging components and printed materials.

          -    that the line is clear of all other packaging material

     A formal documented closure of the packaging line will also be performed;

     5.6 document any deviations in packaging in the related BMR; and

     5.7 keep Key informed of the quality assurance carried out by Valera on its
contract packagers.

6. RELEASE OF FINAL PRODUCT. Valera shall:

     6.1 perform quality assurance tests (including a full documentation review)
on the batch prior to shipment of the Product to Key; and

     6.2 following completion of all quality assurance procedures, supply a full
copy of the batch manufacturing records, including manufacturing records,
packaging records and COAs to Key at the time of shipment of Product to Key.

7. GENERAL. Valera shall:

     7.1 perform stability testing on the Products to the extent required by the
MBR1;

     7.2 keep retention samples of all RM's used in the manufacture of the
Products to the extent required by the MBR1;

     7.3 keep retention samples of each batch of Product to the extent required
by the MBR1;

     7.4 provide test samples with each shipment of the Product to Key, not to
exceed 1 per l00 units of Products shipped to Key or 1 per order if less than
100;

     7.5 perform assay and ID testing, in conformance with the requirements of
the MBR1, on said samples returned to Valera. A COA of the results will be
provided to Key;

     7.6 inform Key of any batch recall or major adverse drug reaction which was
reported to Valera;

     7.7 allow Key or a designated representative to inspect the facilities of
Valera and its contract manufacturers and contract packagers upon reasonable
prior notice during normal business hours. During such inspections, Key will
have access to those facilities of Valera and

                                  CONFIDENTIAL
<PAGE>
its contract manufacturers and contract packagers associated with the
manufacture, testing and packaging of the Product and documentation related to
the manufacture, testing and packaging of the Product. All relevant validation
documentation maintained by Valera or its contract manufacturers and packagers
will also be available. Notwithstanding the foregoing, such inspections shall be
limited to one (1) per calendar year; and

     7.8 supply Key with copies of all inspection reports done by Regulatory
Authorities regarding the Products promptly after receipt of a request from Key
for such report.

8. RESPONSIBILITIES OF KEY. Key shall:

     8.1 accept Final Product Release Responsibility in the Territory;

     8.2 provide Valera with all information relating to possible customer
complaints and keep all records pertaining to such complaints;

     8.3 assist Valera with a possible medicines recall, as well as maintain
procedures for the withdrawal of the Product should that become necessary;

     8.4 assist Valera, as may be needed from time to time, in making any
required changes to the Labels;

     8.5 inform Valera of any regulatory developments within the Territory that
may effect the licence for marketing and sale of the Product in the Territory or
any aspect of this Agreement; and

     8.6 abide by the rules and regulations of Valera during any inspection and
to treat all information as confidential in accordance with Article 12 of the
Agreement.

                                  CONFIDENTIAL
<PAGE>
                                  SCHEDULE 6.9
                   TO THE LICENSE AND DISTRIBUTION AGREEMENT
                                     BETWEEN
                          VALERA PHARMACEUTICALS, INC.
                                       AND
                            KEY ONCOLOGICS (PTY) LTD

                                 RETURNS POLICY

ITEMS ELIGIBLE FOR RETURN

     Returns are limited to outdated merchandise in original packages, whether
returned to Key directly or destroyed at the pharmacy site after approval by a
Key Sales Representative.

TIME LIMIT

     Up to one (1) year after expiry or date of discontinuation.

CREDIT VALUE

     Key's invoiced wholesale price

ITEMS NOT ELIGIBLE FOR CREDIT

1.   Products damaged by fire, smoke, heat or water resulting from a fire or
     other insurable hazards.

2.   Products marked "Non-returnable", "Professional Sample", "Clinical Trial
     Package", or with similar markings or similar labels.

3.   Distress merchandise, such as items purchased from a bankruptcy sale,
     going-out- business sale, fire sale, or other merchandise generally
     considered under the classification "Distress Merchandise" will not qualify
     for credit under the general provision of the Returns Policy.

4.   Merchandise obtained via diverted or other means, including other products
     outside of South Africa.

5.   Unexpired Products.

6.   Overstocked saleable Products returned to Key without prior written
     authorization from Valera.

7.   Products damaged as a result of the negligence or improper storage or
     handling by Key or any third party after delivery of the Product by Valera
     to the carrier.

8.   Products not in its original packaging.

                                  CONFIDENTIAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]